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A TAXONOMY OF REGULATIONS:  THE EFFECT OF REGULATION ON 
SELLING ACTIVITIES 
by 
John F. Riggs 
 
ABSTRACT 
Many companies are faced with rising numbers of regulations with which they 
must comply.  Regulations are particularly common in the areas of employment, 
environmental protection, and licensing of businesses.  In recent years, a growing trend of 
new regulations has emerged in the selling and sales management business environment, 
changing the nature and scope of salespeople’s jobs.  How do regulations affect the way 
salespeople do their jobs?  This is an important and largely unexplored question.  
Therefore, the purpose of this study is to empirically construct a taxonomy of regulations 
that reveals their effect on current selling activities.  A total of 7,493 observations were 
obtained from pharmaceutical representatives via an electronic survey which served as 
the basis for creating factor scores that were subsequently entered into a two-step cluster 
analysis.  The analysis produced a six cluster solution of regulations indicating distinct 
taxonomic structures of regulations that affect selling activities.  The resulting framework 
is useful to researchers, and practitioners, who can view regulations in terms of the 
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CHAPTER 1:  INTRODUCTION 
 
 Many companies are faced with growing numbers of regulations with which they 
must comply.  In fact, there are one or more government agencies that oversee virtually 
every part of a company’s organizational chart.  Regulations are particularly common in 
the areas of employment, health and safety, environmental protection, and licensing of 
businesses:  Environmental Protection Agency (EPA), Occupational Safety and Health 
Administration (OSHA), Equal Employment Opportunity Commission (EEOC), and the 
Federal Trade Commission (FTC) are examples of agencies responsible for regulating 
such areas.   
 Costs associated with regulatory compliance have been reported to cause 
significant burden on companies (Becht, Mayer, and Wagner 2008; Hahn and Tetlock 
2008; Laeven and Levine 2009; Nicoletti and Pryor 2006; Weidenbaum 1998).  The 
seemingly wide spread growth of government regulations placed on businesses continues 
to generate noticeable concern in the United States.  Since 1980, the number of pages of 
regulations in the Code of Federal Regulations has increased from around 1,000 pages to 
over 25,000 pages, a 25-fold increase.   
Rob Portman, a United States Senator from the state of Ohio, reported that beginning in 
2005, a 60 percent increase in pending federal regulations, represents the highest number 
recorded since the government kept count (U.S. Senate Committee 2011). 
 Today, there are 4,226 regulations in the pipeline (The Office of Information and 





affect U.S. businesses, an 11.9 percent increase over 2009.  In a recent statement to 
congress, The Office of Management and Budget (OMB), in accordance with the 
Regulatory Right to Know Act (2000) produced a report that “summarizes estimates by 
Federal regulatory agencies of the quantified and monetized benefits and costs of major 
Federal regulations reviewed by OMB over the last ten years" (OMB, p.3).  The details of 
the report estimated $12.5 billion in annual costs by executive agencies to implement 
regulations.  The Code of Federal Regulations (U.S. Government Printing Office, 2011) 
cataloged over 130,000 pages of regulations from just over 60 federal agencies.  These 
figures estimated that federal agencies generated/issued approximately 4,000 regulations 
annually. 
 Despite the large number of annually issued regulations, virtually all the attention 
has focused on regulatory agencies and regulatory impact at the firm level (Djankov, 
McLiesh, and Ramalho 2006; Hahn et al. 2000; Hemphill 2006 Kolsarici and Vakratsas 
2010).  Such topics as compliance (Breaux and Vail 2006; Hahn and Litan 2005; O'Reilly 
and Chatman 1986), legal (Hahn and Tetlock 2008; Peterson 1994), ethics (Bellizi and 
Bristol 2005; Cavanagh 2004; Ferrell, Fraedrich, and Ferrell 2006; Zoghbi 2010) and 
costs (Becht, Mayer, and Wagner 2008; Crain and Johnson 2001; Hahn and Tetlock 
2008; Sidhu, et al. 2008) are discussed relatively frequently.  However, regulatory control 
is finding its way into functional areas within the firm.  For example, a wide variety of 
laws and sources regulate the marketing function, such as; antitrust laws designed to 
protect consumers against predatory pricing schemes, consumer protection laws that 
provide rules for product warranties and product liability, and intellectual property laws 





Hair, and McDaniel 2011; Pressey and Ashton 2009; Winn and Jondet 2008).  Despite 
these laws, adopted specifically to govern marketing, regulation is no longer unique to 
the marketing function  
 Prior to April, 2003, selling efforts by life sciences firms such as medical device, 
pharmaceutical, and biotechnology had experienced no formal regulatory control over 
their selling activities.  However, on May 5th, 2003, the Office of Inspector General 
(OIG) issued the Compliance Program Guidance for Pharmaceutical Manufacturers 
which prohibited many previously conducted selling activities.  This program sparked the 
beginning of a sequence of newly outlined controls, procedures, and regulations directed 
at selling activities and customer interactions of life sciences companies. 
 Most recently, additional regulatory control has found its way into the selling and 
sales management business environment as demonstrated by the 2009 Code on 
Interactions with Healthcare Professionals published by the Pharmaceutical Research and 
Manufacturers of America (PhRMA).  The PhRMA Code is specific to the 
pharmaceutical industry and regulates how pharmaceutical products and related pre-
launch activities are to be conducted between company representatives and customers.  
For the first time, complying with these codes requires salespeople to change the ways in 
which they conduct selling activities and perform their jobs (Code on Interactions with 
Healthcare Professionals 2009).  
 How do regulations affect the way salespeople do their jobs?  This is an important 
and largely unexplored question.  Although considerable research has been devoted to 
regulation of business at the firm level, companies need to understand the impact of 





threats during the decision process (Jones, Zoltners, and Weitz 2005).  Regulations 
intended to control selling activities are not industry specific.  Numerous selling activities 
are regulated in telecommunications, real estate, energy, tobacco, pharmaceuticals, and 
financial services (Stremersch and Lemmens 2009).  Rationale for regulating various 
selling practices has been attributed to an increase in scrutiny by industry groups, federal 
regulators, and consumer watchdogs on the practice of promotion and personal selling.  
This increased scrutiny has resulted in a labyrinth of new laws, the issuance of revised 
rules, and the creation of specific agencies designed to enforce compliance (Danzon, 
Keuffel, and Rose 2005).  
 Given the current growth of regulatory control, and its potential impact on the 
selling environment, adjusting with innovative approaches and adapting to new selling 
processes is required for both practitioners and academic researchers (Jones, Brown, and 
Zoltners 2005).  Furthermore, the analysis of regulatory effects on selling is significant 
since it may help regulators develop more effective policies.  Therefore, by extending 
taxonomy research to the sales and sales management literature, this dissertation seeks to 
provide a means for organizing sales activities affected by regulations into classes or 
groups that will be amenable to systematic investigation and theory development. 
 The following describes the order of this paper.  First, classification frameworks 
are examined coupled with background information on taxonomies.  Thereafter, 
regulation in business is reviewed, and since selling activities are impacted by the 
presence of regulations (Corneliussen 2005), the literature on selling activities is given an 
overview.  Then, a description of the method employed to analyze the impact of 





complete this study.  The next section of this paper deals with the literature related to the 






CHAPTER 2:  LITERATURE REVIEW 
 
The Need for a Taxonomy 
 
 Sokal and Sneath (1963) reported some of the earliest work on empirical 
taxonomic schemes.  They speculate that many fundamental advances in organizational 
and social sciences were founded on such schemes and are necessary for progress in 
science (Fleishman, Mumford, Zaccaro, and Stephen 1991).  Additionally, taxonomies 
provide researchers the required framework for hypothesis generation (Messick 1989), 
vital structural components, and identify the foundation for theory development 
(Fleishman, Quaintance, and Broedling 1984). 
 Salespeople are faced with growing numbers of regulations that impact their 
selling activities.  For example, three primary factors of selling; developing relationships, 
promotional activities, and entertaining (Moncrief, Marshall, and Lassk 2006) are all 
regulated at the Federal, State, or industry level in numerous industries.  Hence, there are 
regulations on gift-giving, site access, customer provided meals, online events, grants, 
information sharing, and numerous other activities (Boedecker, Morgan, and Stoltman 
1991; Corneliussen 2005).  Examples include, Mount Sinai Medical Center's prohibition 
on gift giving of any value by its vendors, regardless of industry.  Also, the Jackson 
Health System (JHS) in Miami, Florida, has a policy that requires; “all Vendor 
Representatives, prior to engaging in any conversation or communication, for the purpose 
of selling, marketing, or influencing a decision, must first become ‘registered’ with the 





 Another example is how the real estate industry regulates the sharing of 
information.  Because Realtors are bound by certain laws and regulations (Fair Housing 
Act), they cannot tell clients everything they may want and need to know.  Fair Housing 
laws describe the primary function of a real estate agent as connecting or matching 
customers with properties, not providing information about local household income, 
demographics and environmental factors, which is also referred to as “steering”.  
 The high quantity of multifaceted and vague regulations not only makes it 
difficult for companies to know when they are in compliance, but also how to make good 
business decisions.  Since many of these regulations have the force of law, are costly to 
administer, and impact many of the activities used by salespeople, it is important that 
selling organizations are able to organize, understand, and comply with them.  Therefore, 
the first step toward understanding the interaction between regulations and selling tasks is 
to develop an acceptable and usable taxonomy for scholars and managers (McKelvey 
1975). 
 To achieve this undertaking, this research constructs an empirically-based 
regulations taxonomy.  Clusters of federal and industry regulatory activities are the 
classification basis for examining their effect on selling activities.  The taxonomy aims to 
provide a framework for novel investigation, expansion of theory, and development of 
strategy in the area of sales and sales management. 
 
Taxonomies and Typologies 
 
Approaches to Classification 
 
 Taxonomies and typologies are two commonly used conceptual classification 





objects based on one or more characteristics, as typified by the application of cluster 
analysis or other grouping procedures" (Hair et al. 2010).  Bailey (1994) described that "a 
taxonomy uncovers patterns within a set of empirical variables, creating internally 
cohesive clusters or groups."  Alternatively,  
"a typology is a conceptually based classification of objects based on one 
or more characteristics.  A typology does not usually attempt to group 
actual observations, but instead provides the theoretical foundation for the 
creation of a taxonomy, which groups actual observations" (Hair et al. 
2010, p.486).   
 
Thus, “taxonomies are inductive and based on data, while typologies are deductive based 
on theory and require testing for validation” (Hair et al. 2010). 
 Bailey (1994) describes advantages that accompany the development and 
application of taxonomies, many of which promote the current study.  Data integration is 
assisted by taxonomies; their quantitative design provides more valid classifications than 
the subjective nature of typologies; in addition, taxonomies produce variables with more 
specific descriptions than typologies.  However, Bailey (1994) warns that a taxonomy’s 
efficacy can be restricted if the data quality is poor and its measures are incomplete.  In 
addition, interpreting taxonomies can be tricky according to Bailey, and cautions 
researchers about issues related to inference and generalizing.  However, "using careful 
measurement procedures, taxonomies often provide greater understanding of the 
classified phenomena due to their ability to group objects into (relatively) homogenous 
classes" (Bailey 1994). 
 A taxonomy, in its purest form, is an inductive method that attempts to avoid any 
a priori scientific conceptualization.  Hence, the categories are determined by data.  For 






Taxonomies in Business Research 
 
Taxonomies in Business Research (Strategy, Buyer Behavior, Logistics, Sales) 
 
 Scholars have produced decades of research developing and applying taxonomies 
to comprehend how firms gain strategic insights (Bowen 1990; Earl 2001; Hambrick 
1984; Morrison and Roth 1992), how buyers behave (Bunn 1993; Cannon and Perreault 
1999), how sales forces contribute to organizational performance (Homburg, Jensen, and 
Krohmer 2008; Moncrief, Marshall, and Lassk 2006) or how organizations operate via 
logistics (Autry, Zacharia, and Lamb 2008; Hambrick 1984).  One such example within 
the services marketing literature is Bowen's (1990) development of an empirically based 
taxonomy of consumer's perceptions of services.  An interesting outcome from Bowen’s 
taxonomy showed that service managers stayed in a particular industry their entire career.  
This implies that a narrow-minded approach to marketing may encumber creativity and 
innovation, and so marketing insight is limited if services marketers do not look outside 
of their individual industry.  Because of this, a large number of typologies have been 
constructed for grouping services.  However, prior to Bowen’s work (cluster analysis) 
these conceptualizations had not been previously studied. 
 Building on past efforts to categorize buying processes and situations, 
taxonomical research is often used in consumer research (Bunn 1993).  Understanding 
customer buying behavior involves a complex set of issues confounded by many 
situational factors (Cannon and Perreault 1999).  For decades, research scholars and 
marketing managers agree that customers "frame" problems in their own way (Puto 1987) 
and follow self-guided "rules of thumb" to direct their actions in specific situations 





of decisions needed to be made, the creation of buying pattern classifications (taxonomy) 
are central to sustaining research and the establishment of marketing programs that work 
(Bunn 1993).  As an extension of efforts to create classification schemes of buying 
decisions, Bunn (1993) identified six prototypical "buying decision approaches" through 
an empirically based taxonomy development procedure, resulting in a framework that 
views customers segments from the perspective of four fundamental buying activities.  
The findings provide new variations allowing for conceptual extension of the literature as 
well as being useful to marketing managers and researchers alike.  
 In recent years, the growing number of websites where consumers purchase and 
resell products has generated a new area of consumer buying and consumption research; 
consumer-to-consumer (C2C) purchase and resell behavior.  Chu and Liao’s (2007) 
taxonomy of consumer online resale behavior defined and specified how various 
dimensions (i.e., “planned” or “unplanned resell”) impacts consumer’s behavior on 
purchase and resale decisions.  The authors posit that by examining consumer online 
resale and purchasing behavior relationships, the taxonomy supplies a more 
comprehensive picture of online consumer behavior (Chu and Liao 2007).   
 Another area in business research that has a history of developing and applying 
taxonomies is business logistics.  In all areas of today’s market place, an increase in 
worldwide competition has burdened companies with an excess of supply over demand.  
Therefore, the opportunity to make bad supply chain decisions is more present than ever 
(Christopher, Peck, and Towill 2006).  An obvious example can be made by examining 
the execution of “just-in-time” delivery choices.  At the outset, “just-in-time” delivery 





inventory may increase.  At first, this type of decision appeared to avoid cost at one 
company, but could easily transfer increased costs to the supply channel as a whole.  This 
example provides the foundation for why investigators have proposed various supply 
chain taxonomies to extend the present logistics research.   
 Jones (2005) proposes that as research in selling and sales management is 
developing, it is important to appraise the field’s key models, theories, and activities.  
Furthermore, he argues that current selling and sales management research remains based 
upon decades old models and assumptions that “may need revision in light of rapidly 
evolving demands in the marketplace.” 
For example, the relationship between sales and marketing business units has been 
investigated by many researchers (e.g., Biemans et al. 2010; Guenzi and Troilo 2007; 
Homburg and Jensen 2007), however little is known about the existing varieties of 
marketing and sales configurations.  By identifying constructs that compose marketing 
and sales structures, empirically identifying variations of marketing and sales 
configurations, and developing a taxonomy, Homburg, Jensen, and Krohmer (2008) 
illustrate how much variance exists between the attributes of marketing and sales roles.  
Their findings suggest that the strength of the relationship between marketing and sales, 
together with high levels of market knowledge, is the most successful framework. 
 The field of selling continues to be affected by changes in technology, customer 
relationship development, and increased competition, among other environmental factors.  
As such, the breadth and depth of professional sales positions, including the actual selling 
activities and behaviors of selling have also changed significantly (Moncrief, Marshall, 





"that continuing to routinely cite old taxonomies as though they still 
adequately portray today's domain of selling simply is not good research, 
nor does it adequately allow sales organizations and their managers to 
advance successful selling and sales management in practice" (Moncrief, 
Marshall, and Lassk 2006, p.64).  
 
In response to outdated published sales position taxonomies (McMurray 1961; Moncrief 
1986; Newton 1973), Moncrief, Marshall, and Lassk (2006), developed an up to date 
taxonomy of sales positions that considered current selling activities and strategies.   
 By using an updated list of 105 sales activities that reflect contemporary selling 
activities, the author’s identified six new categories compared to previous sales position 
taxonomies (e.g., McMurray 1961; Moncrief 1986; Newton 1973).  Consultative seller, 
new business/channel development seller, delivery seller, sales support, and key account 
seller are selling categories that more accurately reflect present sales jobs and their 
related activities (Moncrief, Marshall, and Lassk 2006).   
 As demonstrated by the examples given, the importance of classification-oriented 
research helps scholars and practitioners organize otherwise unsystematic set(s) of 
complex phenomena by determining patterns and universal traits among groups.  
McKelvey (1975) concludes his seminal article with,  
"The basic inductive-deductive process of science does not work without 
the phenomena under investigation being divided into sufficiently 
homogeneous classes.  Managers cannot use the fruits of science unless 
they first can discern which of all the scientific findings apply to their 
situation" (McKelvey 1975, p.523).   
 
 Because there are numerous approaches to the study of regulations, it is important 
to be explicit about the focus of this research.  For the rest of this paper, I discuss the 
regulating efforts that are intended to facilitate marketing exchanges only, as it is these 





interactions, presenting product information, competitive information sharing, 
entertaining customers, gift giving, and grants.   
 Building on the review of taxonomies in business, the next section explores 
regulation in business, specifically the areas of compliance and cost, including some 
discussion on their impact.  The section concludes with current examples of regulations 
that control selling activities. 




 In general, compliance is defined as “following” rules, requirements, guidelines, 
standards or laws.  Regulatory compliance fundamentally refers to “following” business 
processes, procedures, and practices that are in agreement with sets of or agreed upon 
norms (Lu, Sadiq, and Governatori 2008).  In recent years, high-profile corporate 
scandals involving companies such as WorldCom, Tyco, and Enron has produced new 
types of challenges for companies concerning compliance.  For example, effective 
December 1, 2006, organizations are required to adapt their processes for electronically 
stored information (ESI) during legal proceedings to the new Federal Rules of Civil 
Procedure (FRCP).  Consequently, all companies facing potential U.S. Court 
investigation must comply with the new FRCP at once in order to avoid monetary fines, 
unfavorable case rulings, and business loss. 
 In 2008, Microsoft Corporation, the largest software company in the world, was 
fined by regulators of the European Union 899 million Euros (1.15 billion USD) for 
noncompliance with a 2004 antitrust order (European Commission 2009).  One year 





$30 million USD fine (Environmental Protection Agency 2007).  That same year, York 
International Corporation, a global maker of heating, ventilating, air-conditioning, and 
refrigeration products, was ordered to pay $12 million USD for violations of the U.S. 
Foreign Corrupt Practices Act of 1977 (U.S. District Court 2007).  These types of reports, 
whereby companies incur significant fines for regulatory noncompliance have become 
increasingly common, illustrate the importance of ensuring internal controls are in place 
to address compliance with laws and regulations (Scholz 1984). 
 To further illustrate this point, over 1,300 executives responded to a 2005 Ernst & 
Young survey stating that compliance with regulations exceeded “worms and viruses” as 
the most important item when setting information security policy.  For this reason, 
corporations must make certain that personnel are conscious of and take steps to conform 
to applicable laws and regulations.  In response, companies are implementing regulatory 
compliance frameworks that include compliance policies, standards, measures, and 
training programs.  The intended benefits of such an approach include the assurance of 
corporate control of compliance activities, increased efficiencies, heightened worker 
awareness of compliance standards, and the reduction of legal and financial risks 
(Maignan, Ferrell, and Hult 1999). 
 Recently in 2010, the Food and Drug Law Institute (FDLI) approved disclosure 
legislation requiring life sciences companies (e.g., pharmaceutical, medical device and 
biotechnology) to report sales and marketing promotional expenses (FDLI 2011).  This 
action is the basis for compliance professionals to ensure sales organizations value the 
significance of their activities and maintain compliance.  According to the Food and Drug 





and specific compliance strategies are necessary in today’s highly regulated business 
environment. 
  
Cost of Regulations 
 
 “Although regulations have no direct fiscal impact, they pose real costs to 
consumers as well as businesses” (Hahn et al. 2000).  As recent as 2008, the yearly 
expenditure of federal regulations in the United States grew to more than $1.75 trillion 
(Crain and Hopkins 2010).  Of this amount, the annual direct burden on business is 
estimated at $970 billion, or $8,086 per employee (Crain and Hopkins 2010).  Included in 
these costs are resources employed by government agencies to disseminate, monitor, and 
enforce regulations, as well as the compliance activities by firms (OMB 2009). 
 The development of benefit-cost analysis tools has been the government’s 
response to the soaring monetary costs of regulation (Hahn and Litan 2005).  From the 
perspective of improved efficiency, an example of benefit-cost analysis that enhanced the 
effectiveness of regulation was the 1981 analysis of phasing out leaded gasoline.  This 
was the beginning of the Reagan administration’s plan to eliminate lead in gasoline.  At 
that time, Christopher DeMuth was the official in charge of reviewing the regulation, and 
stated:   
"A very fine piece of analysis persuaded everyone that the health harms of 
leaded gasoline were far greater than we had thought, and we ended up 
adopting a much tighter program than the one we had inherited.  At the 
same time, the introduction of marketable lead permits saved many 
hundreds of millions of dollars from the cost of that regulation" (DeMuth 
and Ginsburg 2010).  
 
 After several analyses, DeMuth and his colleagues reported that constricting the 





years (Hahn and Tetlock 2008).  Three areas contributed to the overall savings; vehicle 
maintenance, decreasing emissions, and reduction in lead-related health issues. 
 The prior example shows how regulation was improved by economic analysis.  
However, Morrison, Winston, and Watson (1999) reported how governments also 
implement regulations where costs exceed benefits.  The Airport Noise and Capacity Act 
of 1990 was studied five years after its inception (1995), and was found to cost over $5 
billion in excess of its projected benefits.  Unintended consequences of this regulation 
included the replacement of 27 percent of the aircraft from U.S. airports earlier than 
budgeted due to the new noise level limits.  This unplanned replacement would cost 
about $10 billion (1995 dollars).   
 The previous research suggests that estimating the payback and expenses of 
individual regulations is not always straightforward.  As seen in the case of leaded 
gasoline, estimating payback can involve complex ways of thinking that connect 
fundamental science to the wellbeing of individuals to the cost of those effects.  
Likewise, expenditures are also complicated and hard to estimate since different 
companies will respond in dissimilar ways regarding the evolution of technology, as seen 
in the case of the Airport Noise and Capacity Act of 1990 (Morrison, Winston, and 
Watson 1999).  Hahn (2005) concludes that "it can be quite difficult to estimate how 
regulatory policy will affect different segments of the population", signaling that the 
quality of analyses of regulation does not meet the basic standards of economic research. 
 Apart from direct monetary costs, Weidenbaum (1998) argues that firms face 
more subtle burdens as a result of regulations.  Fundamental to these are effects on 





alternative that is given up as a result of a decision, suggesting that companies are willing 
to take a "slap on the wrist" and pay a steep fine for not being compliant with regulations 
because financially it is more profitable for the company.  Kambhu (1989) notes when 
companies have the resources to challenge penalties or hide its noncompliance, elevating 
standards may drive compliance down, despite the consequences.   
 A common theme emerges from the various literatures on cost of regulations:  
The process of compliance is both costly and time consuming, and many businesses face 
significant challenges to keep up with the changing laws.  The cost burden, both direct 
and indirect, appears to be unchanging and continues to be a hurdle for businesses to 
thrive and remain a vital part of our economy.   
 
Regulation of Selling 
 
 The impact of regulations has received a lot of interest in finance and accounting 
(e.g., Becht, Mayer, and Wagner 2008, Laeven and Levine 2009, Melis and Carta 2010; 
Piotroski and Srinivasan 2008, Sidhu et al. 2008), economics (e.g., Disdier, Fontagne, 
and Mimouni 2008), as well as marketing (e.g., Friedman and Gould 2007, Kolsarici and 
Vakratsas 2010; Petty and Andrews 2008).  However, prior business literature has 
ignored the role of regulatory requirements in illuminating its impact on selling activities.  
“The fact that sales forces represent a major investment for many firms, with the largest 
sales forces spending billions of dollars a year to deploy and support tens of thousands of 
direct salespeople and their activities” (Zoltners, Sinha, and Zoltners 2001), it makes this 
area of study particularly interesting to academia and practice (Reece and Ahearne 2010; 






Selling Activities and Behaviors 
 
 The one fundamental trait that all sales people have in common is the activity of 
selling.  Regardless of the role or industry, sales people engage in selling activities and 
these activities can be identified readily.  Common selling activities include; building 
trust with customers, sharing product information, overcoming objections, entertaining 
customers, and gift giving (Moncrief, Marshall, and Lassk 2006).  Additionally, work by 
Reid, Plank, and Minton (1997) propose a useful means of conceptualizing sales as an 
interpersonal communication process.  The authors identify getting information, giving 
information, and using information to reflect a communication orientation in selling 
behavior.   
 Reid, Pullins, and Plank (2002) operationalized and tested these measures of a 
salesperson’s communication behaviors for different types of purchase situations.  The 
authors reported that among the six purchasing situations used in their research; (1) 
casual, (2) routine low priority, (3) simple modified rebuy, (4) judgmental new task, (5) 
complex modified rebuy, and (6) strategic new task (Bunn 1993), differences were found 
in the persuasiveness of the salesperson (Reid, Pullins, and Plank (2002).  This research 
suggests that a salesperson’s selling behavior is affected by external/environmental 
situations, in this specific study by purchase situations.      
 
Selling Activity Measure Development Procedure 
 The sales behaviors chosen for the current study were derived following the lead 
from several authors.  The process began by using the 121 sales activities developed by 





defined salesperson behaviors as those involved in “getting” information, “giving” 
information, and “using” information.  This view of sales behaviors is based on the 
observation that communication is fundamental to the selling process (Reid, Pullins and 
Plank 2002).  Finally, the list was further refined from a series of personal interviews and 
focus group sessions with salespeople and sales managers representing banking (NAICS 
521110), real estate (NAICS 531210), pharmaceutical (NAICS 325412), and automobile 
(NAICS 441110) industries because of their known high degree of regulation 
(García‐Canal, and Guillén 2008).   
 Initial personal interviews were conducted at a large pharmaceutical company’s 
annual national sales meeting in central Florida.  The firm’s Vice President of Sales was 
asked to randomly select six to eight associates from his sales organization to participate 
in a focus group discussion regarding selling behaviors and activities.  The discussion 
was conducted in a hotel boardroom with three pharmaceutical sales representatives, two 
district sales managers, and one key account manager.  Each of the participants was 
provided a list of Moncrief’s (1986) 121 selling behaviors and Reid, Plank, and Minton’s 
(1997) 31 sales behaviors.  The participants were asked to “circle” the activities that they 
currently perform in their day-today job as a salesperson.  Following this exercise, a 
“semi-structured interview” focus group was conducted that allowed the interviewer to 
probe and expand on the participant’s responses regarding the relevance each of the 
activities has on their day to day job as a salesperson.  
 In addition to the focus group, a series of three phone interviews were conducted 
with the Vice President of a major U.S. bank, an independent real estate agent, and the 





emailed Moncrief’s (1986) 121 selling behaviors plus Reid, Plank, and Minton’s (1997) 
31 sales behaviors.  Consistent with the focus group procedure, the phone interviewees 
were asked to review the lists for relevance and application by “circling” the activities 
they currently perform in their daily job as a salesperson.  The interviewer individually 
facilitated a “semi-structured interview” with each of the participants to explore and 
develop the participant’s responses.   
 
Classification of Selling Activities 
 
 The classification of an inclusive set of sales activities is a key step in the 
taxonomy development process.  Examining the general selling literature, Moncrief, 
Marshall, and Lassk (2006), and Reid et al. (2002) propose a useful inventory of selling 
behaviors/activities.  In addition, by combining input from the focus group and personal 
phone interviews of industry experts, the sales activities selected for the present study 
were theoretically defined and developed as a means of identifying selling activities 
impacted most by regulations.  Three categories of activities were identified; (1) activities 
that build relationships, (2) activities that facilitate the buying process (getting to buy), 
and (3) activities that aid planning (appendix 6). 
 The first category, “relationship building”, is comprised of relational selling 
behaviors that commonly create strong buyer-seller bonds.  Behaviors such as asking 
questions, listening, and participating in mutual disclosure have been shown to create a 
strong buyer-seller relationship (Crosby, Evans, and Cowles 1990).  In addition, the 
regularity of person-to-person communication between the salesperson and customer in 
the form of customer follow-up has also been acknowledged as a key determinant of 





includes four measures adapted from Reid, Pullins, and Plank (2002); (1) ability to ask 
probing questions, (2) listened to customer, (3) ability to make a charismatic presentation, 
and (4) ability to work well with other people involved in the purchase, plus a fifth 
measure, (5) follow up with customer, which was added by industry interview and focus 
group participants.    
 The second category of selling behaviors, “getting to buy”, includes activities that 
reflect a salesperson’s expertise, and relevant skills associated with knowledge of their 
market, product, customers, and competition.  The salesperson, for example, may use 
their product knowledge to help customers link certain product attributes to their needs, 
answer customer objections, or differentiate his/her product or service from the 
competition.  Therefore three “using information” behaviors and three “giving 
information” behaviors from Reid, Pullins, and Plank (2002) were combined to create the 
“getting to buy” category.  The six “getting to buy” activities are; (1) gain participation 
and got customer involved in the sales presentation, (2) ability to use analogies and 
similes in his/her presentation to help customer see how it relates to his/her situation, (3) 
ability to link his/her product or service attributes to customer needs, (4) able to 
differentiate his/her product or service from the competition, (5) ability to do 
“homework” on customer, and (6) ability to handle objections raised by customer.  Boles, 
Johnson, and Barksdale (2000) reported that a customer is not likely to invest the time or 
effort necessary to build a selling relationship with a salesperson who lacks expertise in 
his/her field.   
 The third and final category of selling behaviors is “planning”.  The acts of 





require significant amounts of salesperson time.  Hence, a lack of planning forces some 
salespeople to choose the customer they see next based on irrational, spur of the moment, 
client pressures (Lodish 1971).  For this reason, we combined four of Moncrief, Marshall, 
and Lassk’s (2006) selling activities with two activities identified from our industry focus 
groups for a combined list of six “planning” behaviors in category three.  They are; (1) 
search out new leads, (2) pre-call planning, (3) designing a sales plan, (4) administrative 
activities and documentation, (5) conduct targeting activities, and (6) business planning.  







Table 1   
Sales Communication Behaviors Measures (adapted from Moncrief, Marshall, and Lassk 2006; Reid, 


















 The preceding list of sales communication behaviors (Table 1), are classified as 
valid measures for examining the potential impact of regulations based on face validity 
ratings by industry experts that included theoretical and practical considerations via focus 
groups.  From an objective perspective, the fact that each identified selling activity can be 
directly linked to some form of regulation further demonstrates the proposed list of 
Relationship Building 
(Reid, Plank, and Minton 1997) 
• Ability to ask probing questions 
• Ability to ask situation questions to try and understand customer needs 
• Used questioning to assess customer needs 
• Ability to ask clarification questions 
• Listened to customer 
• Ability to make a charismatic presentation  
• Ability to work well with other people who are involved in the purchase 
 
(Adapted from industry interviews and focus groups) 
• Follow up with customer 
 
Getting to Buy 
(Reid, Plank, and Minton 1997) 
• Gain participation and got customer involved in the sales presentation 
• Ability to use analogies and similes in his/her presentation to help customer see how it relates to 
his/her situation 
• Ability to link his/her product/service attributes to customer needs 
• Could differentiate his/her product/service from the competition 
• Ability to do “homework” on customer 
• Ability to handle objections raised by customer 
 
Planning 
(Moncrief, Marshall, and Lassk 2006) 
• Search out new leads 
• Pre-call planning/ targeting 
• Administrative activities/ documentation 
 
(Adapted from industry interviews and focus groups) 
• Conduct targeting activities 
• Designing sales plan 





selling activities accurately represents the concept of interest; selling activities impacted 
by regulations.  Three categories of activities were identified; (1) activities that build 
relationships, (2) activities that facilitate the buying process (getting to buy), and (3) 






CHAPTER 3:  METHODOLOGY 
 
 The approach used to build the current taxonomy of regulations that affect selling 
activities, is modeled after the commonly accepted practice formerly put forward by 
Hickson, Pugh, and Pheysey (1969), further developed by McKelvey (1975) and has been 
applied amongst the social sciences (i.e., Bunn 1993; Homburg, Jensen, and Krohmer 
2008; Moncrief, Marshall, and Lassk 2006).  The standard system used to develop 
empirical taxonomy contains four common steps:  The first step identifies the variables to 
be used to form the categories.  Variables are typically derived from several sources.  For 
concepts not clearly specified in the literature, an iterative process of interviews and 
focus groups are commonly used (Moncrief 1986, Moncrief, Marshall, and Lassk 2006).  
The second step--measure development--then produces feedback and an empirical 
foundation on which to specify the variables.  In steps three and four, cluster analysis is 
applied to the data to assemble the objects based on the distinctiveness they possess.  The 
final step "defines the clusters as the categories of the classification scheme--
summarizing the similarities and differences across the categories" (Bunn 1993).   
 Figure 1 shows a five-step procedure for taxonomy development.  The principal 
analytical instrument in taxonomy development is cluster analysis, which assembles “a 
sample of elements (in survey research, often the respondents) such that the statistical 
variance should exhibit high internal (with-in cluster) homogeneity and high external 
(between-cluster) heterogeneity” (Hair et al. 2010).  The primary step in cluster analysis 





Therefore, this taxonomy of regulations that affect selling activities/ behaviors starts with 
the discovery and measurement of applicable sales activities (table 1). 
 
Figure 1 
























STEP   1 
SPECIFICATION 
Methods 
• Review literature 
• Conduct in-depth interviews 
STEP   2 
MEASURE DEVELOPMENT 
Methods 
• Assess reliability/ item-scale discrimination 
• Compute scale scores 
STEPS   3 & 4 
CLUSTER ANALYSIS & PURIFICATION PROCEDURE 
Methods 
• Perform initial cluster analysis 
• Select number of clusters 
• Apply purification procedure 
STEP   5 
MEASURE DEVELOPMENT 
Methods 
• Assess reliability/ item-scale discrimination 








 To construct the functional taxonomy, we must broadly characterize the subject 
area by selecting items pertinent to our area of study, for this project, regulations.  
Therefore, the initial step in creating the proposed regulatory taxonomy of selling 
activities is to develop a typology of regulations that encapsulate the field of sales and 
promotion.  For this paper, the pharmaceutical industry was selected as the primary area 
of study.  This industry is known for its high level of regulation, including all stages of 
product life-cycles, including promotion and selling activities.  Examples include; sales 
representatives are prohibited from providing items for healthcare professionals’ use that 
do not advance disease or treatment education, such as; pens, note pads, mugs, and 
similar “reminder” items with company or product logos (PhRMA 2009).  Another 
example states that companies are prohibited to provide recreational or entertainment 
events in conjunction with promotional and/or educational meetings with customers (OIG 
2006).   
 The complete typology developed here (Appendix 1) is a conceptually based 
classification of regulations based on a broad set of federal, state, industry, and firm 
regulations, thereby ensures that an inclusive list of regulations is incorporated, and 
reducing the risk of omitting a key regulation.  Additionally, only relevant conceptual 
domains were covered in an effort to keep the number of variables parsimonious.   The 
typology does not attempt to group actual observations, but instead provides the 
theoretical foundation for the creation of the proposed taxonomy, which will group actual 





 Toward this end, a two-step selection process was used.  First, to identify the 
conceptual domains and to attain conceptual breadth, websites were reviewed (i.e., 
aba.com; fda.gov; ftc.gov; oig.hhs.gov; phrma.org), coupled with personal conversations 
with select industry executives.  Second, the core constructs contained within each 
conceptual domain were selected.  Constructs were deemed as core if their relevance was 
consistently emphasized in the literature, if they were theoretically grounded, and if they 
applied across companies within the pharmaceutical industry.  The two-step collection 
procedure revealed a total of ninety-four (94) “core” regulations (Appendix 2).  The list is 
comprised of thirty-six OIG, thirty-one PhRMA, nine state, two from the District of 
Columbia, and sixteen firm regulations (figure 2). 
Figure 2 
Initial Categories of “Core” Regulations 
 
Source Number 
Office of Inspector General (OIG) 36 










































 As appendix 1 indicates, regulations in the pharmaceutical industry are 
constituted by four conceptual domains.  Each domain contains core constructs based on 
relevance.  The order of the domains in appendix 1 does not suggest a hierarchical 
structure, especially not in the sense that one domain is a functional prerequisite of 
another; however, they are not completely unrelated.  Thus, conceptually, there is an 
interdependent relationship between domains. 
 The first conceptual domain is federal regulations.  It contains government 
agencies that are the primary regulators of marketing and sales activities of 
pharmaceutical firms.  The three core primary agency constructs are; (1) The Office of 
Inspector General (OIG) of the Department of Health and Human Services, which 
provides compliance procedures for the health care industry.  (2) The Federal Trade 
Commission (FTC), which handle matters affecting consumer protection and competition 
jurisdiction, and (3) The Division of Drug Marketing and Communication (DDMAC) of 
the U.S. Food and Drug Administration (FDA), whose mission is “to protect the public 
health by assuring prescription drug information, is truthful, balanced and accurately 
communicated.” 
 The second conceptual domain is state regulations.  Currently, six states, and the 
District of Columbia are identified as having specific regulatory controls that impact 
selling activities of pharmaceutical companies.  They are; Massachusetts, Maine, 
California, Vermont, South Dakota, Nevada, and the District of Columbia.  The 
remaining forty-five states do not possess individual regulatory controls and only require 





 The third conceptual domain is industry regulations.  The Pharmaceutical 
Research and Manufacturers of America (PhRMA) represents the country’s foremost 
pharmaceutical research and biotechnology companies.  Their mission is “to conduct 
effective advocacy for public policies that encourage discovery of important new 
medicines.”  To that end, PhRMA “developed and enforces regulations that govern 
interactions with healthcare professionals that relate to the marketing of products” 
(PhRMA.org). 
 The final conceptual domain is firm self-regulations.  Pharmaceutical firms have 
developed and implemented numerous internal controls, procedures, and regulations that 
promote adherence to requirements of the federal health care program (FDLI 2010).  
Recognizing that federal guidelines are intended to provide guidance, and often lack the 
force of law, firms attempt to self-regulate their activities by developing and enforcing 
numerous internal self-regulations by means of corporate compliance programs.  These 
programs monitor all agents of the sales and marketing function to prevent and detect 
violations of law or company policy. 
 As the OIG calls for in its Guidance (OIG 2003), pharmaceutical firms tailor their 
corporate compliance programs to fit the unique environment of their company, whether 
it is pharmaceuticals, devices, or diagnostics (Endo 2012; Par 2012; Sanofi 2012).  Once 
companies become aware of possible violations of company policy or law, internal 
investigations are initiated.  Disciplinary action, where appropriate, is taken along with 
any corrective measures to deter possible future violations.   
 The Office of Inspector General (OIG) federal guidelines for pharmaceutical 





Interactions with Healthcare Professionals (PhRMA) are listed in appendix 3.  Both the 
OIG guidelines and PhRMA code regulations are taken directly from their respective 
published documents.  The five states (MA, ME, CA, NV, SD, VT) and the District of 
Columbia regulations were taken directly from their respective Office of the Attorney 
General websites (http://www.atg.state.ma.us, http://www.atg.state.me.us, 
http://www.atg.state.ca.us, http://www.atg.state.nv.us, http://www.atg.state.sd.us, 
http://www.atg.state.vt.us, and http://www.dc.gov) and are listed in appendix 2. 
 
Final Typology of Regulations for this Study 
 The final typology of regulations was derived by subjecting the entire list of 
ninety-four “core” regulations to series of content and face validity checks, which 
produced an inventory of fifty-nine regulations representative of the area being studied.  
Finally, to check for inter-rater reliability, one regulation that fell outside of the 
categories of regulations presented was added, for a total of sixty regulations used for this 
study.  The following discussion describes the steps used for constructing the final 
typology of regulations.   
 The initial step in developing the regulations taxonomy was to subject the entire 
list of ninety-four (94) core regulations (OIG, PhRMA, State, and firm) to thorough 
content analysis, remove replica items and ensure the list only includes unique 
regulations that were relevant to the area of study and effectively represent the subject 
area.  A panel of eight pharmaceutical industry experts (one Vice President of Sales, two 
Regional Sales Directors, four Critical Care Sales Representatives, and one Human 





one PhRMA, nine state, two District of Columbia, and sixteen firm regulations (n=94).  
They were asked to identify duplicate items, validate only those regulations that applied 
to the sales function, and unanimously agree on a final list of regulations that accurately 
reflect their current industry landscape.   
 This iterative process of specification and comparison by eight pharmaceutical 
industry experts collectively identified six federal, two industry, nine state, two District 
of Columbia, and sixteen firm regulations as either extensions or duplicates of existing 
federal and industry regulations.  These thirty-five regulations were therefore combined 
and eliminated from the finalized list, which included the nine state, two District of 
Columbia, and sixteen firm regulations, which completely removed the state and firm 
domains from the final typology.  As a result, the final typology of combined regulations 
contains a complete and parsimonious set of fifty-nine unique regulations described in 
two domains; federal and industry (Appendix 4).  The complete list of regulations used in 
this study is found in Appendix 5.  
 
Survey Instrument 
 Once the sales activity list and the inventory of relevant regulations were created, 
the original survey was formulated to determine the relative significance of each known 
regulation and its perceived effect on the identified selling activities based on 
pharmaceutical sales representative perceptions.   
 Using a seven-point Likert scale (-3 very negatively, -2, -1, 0 not at all, +1, +2, +3 
very positively), respondents were asked to individually rate each regulation's effect on 
their ability to perform the seventeen identified selling activities.  A balanced (equal 





scale was used due to the opposite attributes of the dimensions being studied (Schwarz 
1999).  Since the notion being measured is not a range with the low end of the scale 
representing the absence of the attribute, and instead uses two poles describing opposite 
attributes (“very negatively” and “very positively”), the bipolar numeric properties of the 
scale were chosen.  Furthermore, it appeared logical to use a numbering convention that 
was in concurrence with the nature of the questions so respondents would not be left to 
interpret the meaning of the questions (Schwarz et al. 1991).  Without providing negative 
scores, it was anticipated that subjects may interpret an “all positive Likert scale” (1 to 7) 
as having only a positive impact, and not the presence of negative impact.   
 Since the questionnaire was developed for the purpose of this study, the 
instrument was pretested with pharmaceutical sales representatives.  Representatives 
were asked to examine questions for completeness, in other words, the degree to which 
the list of items effectively encompassed selling activities within the categories of 
regulations presented.  They were also invited to identify any doubt, oversight, or other 
obscurity when answering each activity item, and also to offer ideas for survey 
improvement (De Vaus 2002).  To test for face and content validity, the preliminary 
survey containing the complete list of fifty-nine regulations and twenty selling behaviors 
was appraised by eleven first-line sales managers and twenty-six sales representatives 
attending their company national sales meeting in the northeastern United States. 
 In addition, one retired and four current senior level pharmaceutical executives, 
who were not employees of the sample frame, appraised the survey from the perspective 
of specificity, readability, accuracy, and internal and external validity.  Based on 





questions”, “used questioning to assess customer needs”, and “ability to ask clarification 
questions”) were removed since they were deemed duplicative and redundant.  Hence, the 
removal of these three behaviors from the original twenty measures produced a revised 
total of seventeen items.  Finally, to measure inter-rater reliability, one regulation was 
added to the original fifty-nine that fell outside of the categories of regulations presented; 
“Speakers and their materials must clearly identify the company that is sponsoring the 
presentation.”  This question was independently coded and used to compare the degree of 
agreement among raters.   
 To assess the generalizability of the study, and to establish inclusion criteria for 
participants, the final survey included queries about respondent job title, position, and 
qualified experience.  A website was used as placement for the survey to facilitate ease of 
data gathering. 
 
Randomized, Multicenter, Parallel-Arm Clinical Research Trial Design 
 Given our research objective of empirically developing a taxonomy of sixty 
identified regulations that accurately reflect their effect on seventeen recognized selling 
activities, the projected questionnaire would contain 1,020 items.  Clearly, the issue of 
questionnaire length became a major concern.  With such an extensive survey, 
“respondents might not answer properly at later stages of the questionnaire or may stop 
filling the questionnaire out” due to respondent fatigue and boredom (Berdie 1989).  
Based on strong conceptual support predating the application of the technique, the 
primary investigator felt that the number of regulations and the number of selling 





by medical researchers (Appel 2006; Localio et al. 2001). "Randomized, multicenter, 
parallel-arm clinical research data gathering design", as an effective tool to reduce 
respondent burden without making trade-offs between the amount and quality of 
information obtained. 
 Medical researchers commonly use more than one medical center or clinic to 
gather clinical trial data.  This method is known as “multicenter research trial” design.  In 
addition, multiple treatment groups (“arms”) are established to test at least two 
medications (e.g., treatment A and treatment B).  Study participants are randomly 
assigned one of the respective treatments.  This type of study design using “parallel-
arms” provides remarkable efficiency by testing multiple treatments in identical 
populations simultaneously (Appel 2006).  The sample size is typically similar across 
parallel arms such that there is no interaction linking treatments.  Hence,  
“if there is no interaction between therapies, then one can test the effect of 
treatment A by combining the results across groups, regardless of whether 
they receive treatment B.  Likewise, one can test the effect of treatment B 
by combining the results across groups, regardless of whether they receive 
treatment A” (Appel p.1360).  
 
Due to the large number of required subjects, most large clinical trials are conducted at 
numerous clinical research centers.   
 A key requirement when conducting a multicenter, parallel-arm research trial is 
the establishment of patient or subject “inclusion criteria”.  Inclusion criteria are a 
method of establishing precision in your cohort.  In medical research for example, the 
investigator might suspect that a new brand of hypertension medicine is more effective 
than an existing brand, but for some reason this seems to be true only for female patients 





information and the investigator's professional knowledge, he can establish specific 
inclusion criteria for his study.  More specifically, inclusion criteria are the criteria or 
standards that specify which subjects are to be included in the study lending to increased 
generalizability.  In medical research trials, inclusion criteria may include demographic 
data, previous medical history, disease states being investigated, and related medical 
conditions.  “Inclusion criteria help identify suitable participants” (Agency for Healthcare 
Research and Quality AHRQ.gov).  It is necessary that these criteria be objective and 
clearly defined, so that those involved in the study (or investigators trying to duplicate the 
study) can replicate participant inclusion decisions accurately. 
 In summary, randomized, multicenter, parallel-arm trials allow clinical 
investigators to include larger numbers of participants, longer data gathering tools such as 
surveys, diverse geographic locations, the inclusion of broader population groups, and the 
ability to compare results among participants, all of which increase the generalizability of 
the study (Localio et al. 2001).  The current study is a randomized, 3-arm parallel group, 
multicenter study assessing the effect of regulations on selling activities in 
pharmaceutical sales representatives.  It mirrors randomized, multicenter, parallel-arm 
research trial design methodology with inclusion criteria standards, thereby permitting us 
to collect responses from three separate arms (surveys),  and test and combine a large 
number of observations (n=7493), regardless of which survey the respondent  received 
(Appel 2006; ACRP 2012).  This method is unknown in marketing research and is 
therefore a new alternative to the heuristic methods that are currently used when massive 







 The initial survey instrument contained sixty (60) regulations of which 
respondents would be asked to rate each of the seventeen (17) selling activities.  In order 
to reduce “respondent burden” and reduce survey length, multicenter, parallel-arm 
research trial design methodology and inclusion criteria standards were applied which 
divided the original list of sixty (60) regulations into three separate surveys containing 
twenty (20) regulations each.  A random number generator was used to create a sequence 
of twenty (20) regulations coupled with the same selling activities in order to develop 
three respective questionnaires that lack any pattern.  Each respondent was asked to rate 
seventeen (17) identical selling activities based on the impact of the twenty (20) 
respective regulations listed.  In addition, each version contained the same demographic 
questions, and descriptive variables at the firm level.  Exactly twenty (20) regulations, 
one-third of the complete list, appeared on each of the three versions of the survey; 
therefore, all respondents did not complete all scales.  Each of the three versions of the 
survey is found in appendix 7.   
 
Sample Frame and Primary Data Collection 
 Subsequently, the next phase in the process of taxonomy development is to gather 
data for the purpose of dividing the sample into meaningful groups.  As outlined in the 
conceptual model, primary data collection was from the pharmaceutical industry.  
Pharmaceutical firms are highly regulated in nearly all stages of the product life-cycle, 






sample for this research (Danzon, Keuffel, and rose 2005).  Hence, the pharmaceutical 
industry provides a good context in which to develop and test this model. 
 In keeping with the multicenter, parallel-arm clinical research trial methodology, 
a feasibility study was performed.  A feasibility study is typically performed as part of the 
planning process before the initiation of a new clinical study (Hagen et al. 2011).  One of 
the biggest challenges of initiating a new clinical research trial is the identification and 
recruitment of the appropriate patient population for the study.  The feasibility sample 
frame for this study consisted of phone interviews with company officials from six 
respective pharmaceutical firms.  The interviews were used to ascertain the level of 
response, company interest, and ability to satisfy a pre-established set of participant 
inclusion criteria.  A subject may be included in the study if all of the following criteria 
are met: 
Inclusion Criteria: 
1. Currently employed by a pharmaceutical firm that is a member of the 
Pharmaceutical Research and Manufacturers of America Association (PhRMA).  
Since PhRMA regulations are a key aspect of this study, this criterion is necessary 
for inclusion since not all pharmaceutical companies are members of PhRMA.  
By requiring participants to be currently employed by a pharmaceutical company 
that is a member, we ensure that all respondents are subject to the regulations 
being studied.   
2. Currently works as a salesperson, account representative, managed care 
representative, or marketing manager.  This criterion was established to ensure 





marketing regulations.  Since our area of study is not appropriate for “jobs” 
outside of the sales function, this condition safeguards against the inclusion of 
respondents who would not be suitable participants. 
3. Works in primary care, specialty, hospital, or account management division.  
Pharmaceutical firms typically have numerous “divisions” that target unique 
customer segments, support different company functions, etc.  These four 
divisions include the majority of sales representatives and the regulations being 
studied.  Therefore, it was important to specify “divisions” that are subjected to 
the regulations being studied in order to exclude divisions that are not.  (For 
example: contracting, medical affairs, and distribution.) 
4. Successfully completed a training program on “pharmaceutical promotional 
practices and guidelines”. This criterion ensures that respondents have a similar 
level of awareness of the regulations and understands expectations regarding 
compliance.  This standard removes the possibility of a respondent not being 
previously aware of the regulations being studied.  
 For construction of the taxonomic system described here, only pharmaceutical 
salespeople who met all of the above inclusion criteria were used.  A sample of 489 
pharmaceutical sales representatives was randomly drawn from a large U.S. 
pharmaceutical firm that employs 1,000 sales professionals.  A total of 396 completed 
surveys were submitted via a website generating an overall response rate of 80.9 percent.  
After surveys with more than 5 percent of missing data were removed (Little and Rubin 






response rate of 77.9%.  The remaining data from the 381 surveys were used to create the 
taxonomy.  Respondent demographics are reported in the table 2 below. 
Table 2 











Gender   
   Female 189 (49.6%) 63 (51.2%) 65 (51.2%) 61 (46.7%) 
Male 192 (50.4%) 60 (48.8%) 62 (48.8%) 70 (53.4%) 
     Age 
    18 to 25 years 90 (23.6%) 28 (22.8%) 26 (20.5%) 36 (27.5%) 
26 to 35 years 100 (26.2%) 36 (29.2%) 36 (28.3%) 28 (21.4%) 
36 to 45 years 86 (22.6%) 26 (21.1%) 30 (23.6%) 30 (22.9%) 
46 and older 105 (27.6%) 33 (26.8%) 35 (27.6%) 37 (28.2%) 
     Education 
    Associates Degree 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Bachelors Degree 159 (41.7%) 54 (43.9%) 54 (42.5%) 51 (38.9%) 
Masters Degree 213 (55.9%) 65 (52.8%) 70 (55.1%) 78 (59.5%) 
Doctoral Degree 9 (2.4%) 4 (3.3%) 3 (2.4%) 2 (1.5%) 
     Education Other 
    MD 1 0 0 1 
ARNP 5 2 2 1 
RN 15 5 6 4 
LPN 5 1 2 2 
Paramedic (PMD) 3 1 1 1 
EMT 3 1 1 1 
Cath Lab Tech 1 0 0 1 
Lab Tech 1 0 0 1 
     Selling Experience 
    Less than 1 year 31 (8.1%) 8 (6.5%) 11 (8.7%) 12 (9.2%) 
1 to 5 years 114 (29.9%) 28 (22.8% 25 (19.6%) 61 (46.6%) 
6 to 10 years 86 (22.6%) 23 (18.7%) 35 (27.6%) 28 (21.4%) 
11 to 15 years 56 (14.7%) 19 (15.4%) 26 (20.4%) 11 (8.4%) 
16 to 20 years 56 (14.7% 24 (19.5%) 20 (15.7%) 12 (9.2%) 














































    Less than 1 year 51 (13.4%) 9 (7.3%) 16 (12.6%) 26 (19.8%) 
1 to 5 years 114 (29.9%) 34 (27.6%) 33 (25.9%) 47 (35.9%) 
6 to 10 years 96 (25.2%) 23 (18.7%) 37 (29.1%) 36 (27.4%) 
11 to 15 years 53 (13.9%) 19 (18.7%) 20 (15.7%) 14 (10.7%) 
16 to 20 years 47 (12.3%) 23 (18.7%) 17 (13.3%) 7 (5.3%) 
More than 20 years 20 (5.2%) 15 (12.2%) 4 (3.1%) 1 (0.7%) 
     Company Experience 
    Less than 1 year 107 (28.1%) 24 (19.5%) 27 (21.3%) 56 (42.7%) 
1 to 5 years 123 (32.2%) 45 (36.6%) 38 (29.9%) 40 (30.5%) 
6 to 10 years 86 (22.6%) 25 (20.3%) 37 (29.1%) 24 (18.3%) 
11 to 15 years 35 (9.2%) 16 (13.0%) 12 (9.4%) 7 (5.3%) 
16 to 20 years 28 (7.3%) 11 (8.9%) 13 (10.2%) 4 (3.0%) 
More than 20 years 2 (0.5%) 2 (1.6%) 0 (0.0%) 0 (0.0%) 
     Region 
    Northeast 73 (19.2%) 24 (19.5%) 26 (20.5%) 23 (17.5%) 
Southeast 99 (25.9%) 32 (26.0%) 33 (25.9%) 34 (26.0%) 
Caribbean 7 (1.8%) 3 (2.4%) 3 (2.4%) 1 (0.8%) 
Central U.S. 29 (7.6%) 9 (7.3%) 9 (7.1%) 11 (8.4%) 
North Central U.S. 64 (16.8%) 18 (14.6%) 19 (15.0%) 27 (20.6%) 
Southwestern U.S. 40 (10.4%) 14 (11.3%) 14 (11.0%) 12 (9.2%) 
Northwestern U.S. 56 (14.6%) 19 (15.4%) 19 (14.9%) 18 (13.7%) 
Nationally (entire U.S.) 13 (3.4%) 4 (3.2%) 4 (3.1) 5 (3.8%) 
     College Major 
    Marketing 137 (35.9%) 52 (42.3%) 42 (33.1%) 43 (32.8%) 
Finance 35 (9.2%) 6 (4.9%) 13 (10.2%) 16 (12.2%) 
Accounting 19 (5.0%) 8 (6.5%) 11 (8.7%) 15 (11.4%) 
Sales 19 (4.9%) 0 (0.0%) 3 (2.4%) 1 (0.8%) 
Education 11 (2.9%) 8 (6.5%) 2 (1.6%) 1 (0.8%) 
Psychology 18 (4.7%) 4 (3.2%) 6 (4.7%) 8 (6.1%) 
Health Related 90 (23.6%) 24 (19.5%) 31 (24.4%) 35 (26.7%) 
Computer Science 4 (1.0%) 2 (1.6%) 2 (1.6%) 0 (0.0%) 





CHAPTER 4:  DATA ANALYSIS AND FINDINGS 
Results 
 Reflecting the process used by Moncrief, Marshall, and Lassk (2006), the 
qualitative stage of our data analysis was followed by a two-step quantitative analysis:  
factor analysis and cluster analysis.  Primary groupings of the data were initially 
identified using factor analysis, followed by cluster analysis to create the actual 
regulation taxonomy.  Other analyses, primarily cross-tabulations, were executed 
throughout the procedure to help describe and clarify the individual clusters (Moncrief, 
Marshall, and Lassk 2006). 
 Using the multicenter, parallel-arm clinical trial data gathering method, 
aggregating or "stacking" the responses from three individual questionnaires, generated a 
three-dimensional data set whereby each survey includes approximately one-third of the 
7,493 total observations generated by 381 respondents.  It was necessary to convert the 
original three-dimensional data set into a two-dimensional measure in order to accurately 
factor analyze the overall sample.   
 This conversion was accomplished by pooling the respondent’s ratings for each of 
the seventeen respective selling activities by individual questionnaire.  The pooled data 
was then calculated into means for the purpose of creating more reliable and valid 
measures (Gomez-Mejia, Tosi and Hinkin 1987; Zajac 1990).  To illustrate the process, 
one hundred twenty-three respondents rated seventeen selling activities for regulation 
one, which created a three-dimensional data set.  Means were then calculated by 
averaging each of the one hundred twenty-three responses per individual selling activity 





point Likert scale, the average rating of one hundred twenty-three respondents regarding 
the impact regulation one has on selling activity one is 4.00813.  Likewise, using the 
same scale, the average rating of one hundred twenty-three respondents regarding the 
impact regulation two has on selling activity one is 4.01626.  This methodology was 
applied to the entire sample of three hundred eighty-one respondents and then, as with the 
Moncrief (1986) study, the means were used as the clustering basis. 
 
Factor Analysis 
 To generate meaningful categories (in this study, regulations affecting selling 
activities), factor analysis using SPSS 17.0 was executed.  An unweighted least squares 
model with an oblique rotation was specified to minimize further bias and allow 
correlation. 
 The scree plot (figure 3) indicated a three-factor model.  The explained variance 
by the three factors was 82.6 percent.  A score of .4 was used as a cutoff to indicate 
inclusion in a factor.   As shown in table 2, fifteen of the seventeen indicators clearly 
loaded on one of the three factors.  Variables v1, v2, v3, v4, and v16 highly loaded on 
factor one; variable two is characterized by variables v5, v6, v7, v8, v9, and v10; and 
factor three has four distinctive characteristics (v11, v12, v13, v14).  As shown, v15 and 
v17 have significant loadings on factors two and one respectively.  Since two variables 
are given on both of these factors, v15 and v17 were deleted from the analysis (Hair et al. 
2010).  As noted in the table, the factor structure for the remaining fifteen variables is 
now well defined, representing three distinct groups of variables that are consistent and 







Activities Affected by Regulations Factor Analysis 
 
          
                                                        Pattern Matrix Maximum Likelihood Analysis Oblimin Rotation Factor¹ 
  
 





Skills Planning   
Indicator 
    
Ability to ask probing questions (v1) .934 
   
Listened to Customer (v2) .942 
   
Ability to make a charismatic presentation (v3) .887 
   
Ability to work well with others involved in purchase (v4) .859 
   
Follow up with customer (v16) .900 
   












































Administrative activities/documentation (v17) .462 .505     
Note.  Bolded items represent cross-loadings and were therefore eliminated from the analysis  
  ¹Loadings less than .40 are not shown and variables are sorted by highest loading 








Description of the Factors 
 Following the preliminary selling activity groupings, each group was examined 
and given a name that identifies it by the correlating nature of the selling activities (Hair 
et al. 2010).  The following three selling activity groups emerged from the factor 
analysis. 
 Factor 1:  “Customer Relationships through Communication" (activities x1, x2, 
x3, x4, x16).  The five items that load onto factor 1 relate to activities associated with 
building relationships with customers through relational communication skills such as 
asking questions, listening to the customer, ability to make a charismatic presentation, 
and follow-up with the customer.   Thus, this factor was labeled “customer relationships 
through communication.”  Building customer relationships through communication 
focuses on the “process” of communication (i.e., the how rather than the what), and is 
maximized by brief social encounters, as well as, longer, ongoing interactions (Grissom, 
Erchul, and Sheridan 2003).       
 Factor 2:  "Core Selling Skills" (activities x5, x6, x7, x8, x9, and x10).  Factor 2 





changing customer perceptions through reason or figurative means.  This factor is 
comprised of six activities that represent foundational selling skills such as linking 
products to customer needs, differentiating products from the competition, ability to 
handle customer objections, and the ability to use influential presentation skills to relate 
to customer needs.  Factor 2 was therefore labeled “core selling skills”.  Sales people 
make use of these “core selling skills” as a way to change customer perceptions and 
influence customer decision making. 
 Factor 3:  “Planning” (activities x11, x12, x13, and x14).  Items for factor 3 
identified selling activities that help sales people prepare for customer interactions.  The 
act of “planning” for a salesperson is much like “pre-game” activities for sports teams.  
These are the activities that build a structured understanding that sales people use to 
become organized, mentally prepared, and solve problems so that everything is “routine” 
when the sales person is in front of a customer (game-time).  Prospecting skills such as 
searching out new leads, pre-call planning, conducting targeting activities, and designing 
a sales plan are the selling activities that created Factor 3.  
 By factor analyzing selling activities from a regulatory impact point of view, we 
obtained three distinct groups (factors) which generated a novel way to organize selling 
activities (appendix 8).  While the three factor solution reported here generated 
meaningful categories, it is important to note that the results are specific to the industry 
studied (pharmaceutical) and represent the interaction between identified regulations and 
selling activities.  As such, our results do not represent generalizability and are subject to 







 The objective of the clustering stage was to group different regulations into 
descriptive classifications.  Due to our large data set (7,493 observations) and the need to 
vary large numbers of clusters, the two-step clustering approach, developed by Chiu et al. 
(2001) was chosen to develop the taxonomy.  “Unlike hierarchical clustering which 
requires a matrix of distances between all pairs of cases, and the k-means algorithm that 
requires "shuffling" objects to and from clusters” (Norusis 2008), the SPSS TwoStep 
Cluster Analysis requires only a single pass of data, and can produce solutions for large 
data sets for varying numbers of clusters. 
 Within SPSS 17.0, the two-step cluster method relies on the "auto clustering" 
procedure when shaping the number of clusters that represents the data sample.  The 
calculation first measures the lowest Schwarz Bayesian Information Criterion (BIC), and 
then the algorithm adjusts the result by considering solutions with a large "Ratio of 
Distance Measure", thus generating the optimal number of clusters.  Replication studies 
have shown that BIC and AIC in combination (Two-Step Cluster) work better than BIC 
or AIC alone (SPSS 2001).  The analysis created six definite clusters which will be 
described and discussed in the following section. 
 When performing a two-step cluster analysis within SPSS 17.0, the investigator 
has the opportunity to supersede the "auto-clustering" default and perform any number of 
cluster iterations as a cross-validation procedure to corroborate the appropriate number of 
clusters for the final cluster solution.  After five iterations, the procedure was terminated 
because none of the observations changed membership and the clusters were stable (Bunn 





 Moreover, cross-tabulations were performed, crossing each regulation by selling 
activity, cluster, and a number of demographic variables.  The cross-tabulations added 
value when clarity was needed in interpreting the clusters.  Group (cluster) association 
after this process was the final assignment of the observations to clusters.  In the 
following results section, we list the major factors that play a part in defining each of the 
six clusters - either positively, negatively, or no role at all.   
 
Classification and Interpretive Description of Clusters: 
 The two-step cluster analysis produced a six cluster solution, which will be 
described in this section.  The clusters are reported in descending rank order based upon 
total number of regulations comprised in each respective cluster.  For example, Cluster 1 
contained the largest number of regulations (19), while Cluster 6 contained the least (4).  
The following cluster tables contain the specific regulation number assigned for this 
study, as well as a brief paraphrased description of the actual regulation.  The actual 













Cluster 1:  Highly Restrictive Regulations (29.7 Percent of Observations) 
Cluster 1:  Highly Restrictive Regulations 
Regulation 4 – Manufacturer is prohibited from coupling services that confer a benefit to provider 
Regulation 5 – Sales and marketing functions are prohibited from providing grants 
Regulation 11 – Relationships with customers should not influence decisions for referrals 
Regulation 15 – Compensating physicians for services related to sales and marketing activities are prohibited 
Regulation 16 – Compensating physicians for time spent listening to sales presentations are prohibited 
Regulation 18 – Entertainment, recreation, and travel in association with sales activities are prohibited 
Regulation 19 – Gifts, gratuities, and other business courtesies are prohibited 
Regulation 25 – Meals offered by sales representatives must be limited to in-office or in-hospital settings 
Regulation 26 – Inclusion of a healthcare professional’s spouse or guest at a meal is prohibited 
Regulation 28 – Companies are prohibited from providing any entertainment or recreational items 
Regulation 32 – Financial support is prohibited for expenses of non-faculty healthcare professionals 
Regulation 35 – Financial support is prohibited for healthcare professionals for professional meetings 
Regulation 37 – Sponsoring companies are prohibited to influence conference content, venue or faculty 
Regulation 38 – Financial support for the cost of personal expenses at conferences are prohibited 
Regulation 46 – Companies are prohibited from providing recreation or entertainment at meetings 
Regulation 47 – Honoraria and travel expense payments are prohibited at company sponsored meetings 
Regulation 56 – Items intended for personal benefit (such as floral arrangements) is prohibited 
Regulation 57 – Payments in cash or cash equivalents (such as gift certificates) are prohibited 
Regulation 59 – Items designed for education of patients should only be offered  on an occasional basis 
 
Centroids 
    Customer Relationships Through Communication 
Core Selling 
Skills Planning 








Cluster 1 -2.81 .278 -2.82 .230 -1.82 .477 
 
 The "highly-restrictive regulations" group had the lowest negative scores among 
the clusters and contains the largest number of regulations from the overall sample.  
Nineteen of the sixty regulations studied (31.7%) were perceived as highly negative by 
salespeople in each of the selling activity categories.  In this group, regulations impacting 
a salesperson's ability to perform "core selling skills" scored the lowest (-2.82) among all 





scored -2.81 followed by "planning" activities at -1.82.  This cluster ranks last on each 
centroid and contains the largest number of observations (n=2224) of the sample.   
 This finding indicates that the majority of respondents studied perceive a 
preponderance of regulations as negatively affecting (restricting) their ability to build 
relationships through communication (relationally communicate), use their core selling 
skills, and plan.     
 
Cluster 2:  No Effect Regulations (27.4 Percent of Observations) 
Cluster 2:  No Effect Regulations 
Regulation  1 – Offer or payment of anything of value for patient referrals are prohibited 
Regulation  2 – Remunerative relationships must be identified between company and 
customers/speakers/consultants 
Regulation  3 – Information provided to decision-makers, patients, customers must be accurate and 
complete 
Regulation  7 – Manufacturer must document grant making and educational presentations regularly 
Regulation  8 – Any payments to cover the costs of “converting” from a competitor product is prohibited 
Regulation  9 – Selective offers of remuneration is prohibited 
Regulation 13 – “Switching” arrangements involving cash or other benefits are prohibited 
Regulation 14 – Consulting and advisory payments must be at fair market value to bona fide consultants 
or advisors for their services 
Regulation 29 – Giving of any subsidy directly to a healthcare professional by a company is prohibited 
Regulation 39 – Consulting agreements are prohibited to serve as either inducements or rewards for 
prescribing or recommending a particular medicine or course of treatment 
Regulation 41 – A legitimate need for the consulting services must be clearly identified in advance 
Regulation 43 – The number of healthcare consultants retained must not exceed the number reasonably 
necessary to achieve the identified purpose 
Regulation 50 – Companies must establish policies for the appropriate use of speakers and their training 
Regulation 52 – Speaker programs must be monitored for compliance with FDA requirements 
Regulation 53 – Healthcare professionals serving as consultants, speakers, or advisors are required to 
disclose the existence and nature of his/her relationship with the company 
Regulation 60 – Grants, scholarships, subsidies, support, gifts, etc are prohibited as exchange for 









    Customer Relationships Through Communication 
Core Selling 
Skills Planning 








Cluster 2 -.05 .258 -.07 .315 .10 .388 
 
 The "no effect" cluster is the second largest group (n=2052) of observations in the 
study, representing 27.4% of the sample.  Unlike the other five clusters, cluster 2 contains 
regulations that salespeople perceive having no effect on their selling activities.  On a 
seven-point Likert scale, where -3 indicated "very negatively" and +3 indicated "very 
positively", this group reported sixteen of the sixty regulations (27.6%) to have little to 
no effect on selling activities.  "Customer relationships through communication" was 
impacted the least (-.05) followed closely by "core selling skills" (-.07).  The final factor, 
"planning" scored slightly higher (.10), however not high enough to differentiate it from 
the grouping.     In other words, cluster 2 contains regulations viewed as having neutral 
impact on selling activities.   
 
Cluster 3:  Somewhat Restrictive Regulations (16.6 Percent of Observations) 
Cluster 3:  Somewhat Restrictive Regulations 
Regulation 6 – Manufacturer is prohibited from having control over speaker or speaker content 
Regulation 10 – Relationships with formulary committee members prohibited to influence decisions 
Regulation 21 – Promotional materials must be consistent with approved FDA requirements and 
cannot be altered, highlighted, etc. 
Regulation 31 – The company is prohibited to provide any advice or guidance to CME providers 
Regulation 33 – Funding is prohibited to compensate for time spent for participating in CME events 
Regulation 42 – Criteria for selecting consultants must be directly related to the identified purpose 
Regulation 45 – Venue and circumstances of any meeting with consultants are conducive to 
consulting services and activities related to purpose of meeting; resorts are not appropriate venues 








    Customer Relationships Through Communication 
Core Selling 
Skills Planning 
    





Cluster 3 -1.55 .646 -2.26 .443 -1.08 .527 
 
 This group ranked third in overall negative impact (16.6%) with 1241 overall 
observations.  Of the three centroids, "core selling skills" had the lowest negative score (-
2.26) ranking it the fourth most negative category among all groups.  "Customer 
relationships through communication" and "planning" scored slightly better, however 
they were all perceived as negative.  Cluster 3 is still relatively low on all measures and 
contains eight of the sixty regulations (13%) studied.  This group was most similar to 
cluster 2 with respect to overall negative impact.   
 
Cluster 4:   Restrictive in Office Regulations (11.2 Percent of Observations) 
Cluster 4:  Restrictive in Office Regulations 
Regulation 12 – Good or services provided to eliminate an expense that the physician would have 
otherwise incurred is prohibited 
Regulation 17 – Payments for time spent accessing web sites to view or listen to marketing 
information or to perform research is prohibited 
Regulation 27 – Offering “take-out” meals or meals to be eaten without a company representative 
present is prohibited 
Regulation 44 –The retaining company must maintain records for consulting services provided 
Regulation 49 – Companies are required to “cap” the total amount of speaker compensation it will 
pay annually 
Regulation 55 – Promotional items such as; pens, note pads, mugs and similar “reminder” items 
with company logos or product names are prohibited 
Regulation 58 – Items designed for education of patients must be $100 or less in value 
 
Centroids 
    Customer Relationships Through Communication 
Core Selling 
Skills Planning 
    










 This category contains two factors that were slightly negative, and equally 
revealed minimal factor centroid values and rankings; "core selling skills" (-.59) and 
"customer relationships through communication" (-.97).  "Planning", the third factor, 
reported a much more negative score (-1.55) indicating that activities such as searching 
out new leads, pre-call planning, conducting targeting activities, and designing sales 
plans were more negatively impacted by this group of regulations.   
 
Cluster 5:  Bad with Customer / Good in Office (8.5 Percent of Observations) 
Cluster 5:  Bad With Customer / Good In Office Regulations 
Regulation 23 – Occasional meals may be offered, so long as the presentation provides scientific value 
Regulation 30 – Financial support must be given to the CME provider directly 
Regulation 34 – It is prohibited to provide meals directly at CME events, except that the CME provider may 
apply the financial support from the company to provide meals for all participants 
Regulation 36 – Financial support for conference registration fees must be given directly to the conference 
sponsor and not to participants 
Regulation 54 – Financial assistance for scholarships or other educational funds to support medical 
students, residents, or fellows may not be offered directly, but may be offered to the institution 
 
Centroids 
    Customer Relationships Through Communication 
Core Selling 
Skills Planning 








Cluster 5 -2.29 .387 -1.81 .373 1.14 .402 
 
 Examination of the fifth group (636 observations) shows that “customer 
relationships through communication” and “core selling skills” were both negative (-2.29 
and -1.81 respectively).  “Planning” on the other hand was positive at 1.14.  Cluster 5 is 
unique compared to the other clusters such that no other clusters reported a mix between 






Cluster 6:  Helpful Regulations (6.7 Percent of Observations) 
Cluster 6:  Helpful Regulations 
Regulation 20 - Promotional material claims must be fair and balanced 
Regulation 22 - Meals may be offered to customers and staff as long as they are modest in value 
Regulation 24 – Occasional meals must be accompanied by educational or scientific presentations 
Regulation 40 – Written contracts must specify the nature of consulting services to be provided 
 
Centroids 
    Customer Relationships Through Communication Core Selling Skills Planning 








Cluster 6 2.55 .500 2.39 .711 2.54 .439 
 
 
 This group scored the highest with respect to regulations that are perceived by 
salespeople as "helpful" when performing selling activities.  On a scale of -3 to +3, this 
group had the highest mean score on "customer relationships through communication" 
(2.55), "core selling skills" (2.39), and "planning" (2.54).  This category of regulations 
includes the approval of activities such as providing meals to customers and staff, the 
initiation of contracts with customers to enforce agreed upon services, and requirements 
of firms to substantiate product claims.  Each of these regulations was perceived by 
salespeople to facilitate communication with prospects, assist their interpersonal 
influencing efforts, and support planning efforts.  Thus, this cluster was labeled “helpful” 
indicating that the majority of sales people perceived regulations 20, 22, 24, and 40 as 
useful.  "Helpful Regulations" is the smallest cluster representing just 6.7% of 7493 total 
observations.  Four of the sixty regulations included in this study reside in cluster six.  
This finding indicates that less than 7 percent of the regulations examined are perceived 





CHAPTER 5:  CONCLUSION, LIMITATIONS, AND FUTURE RESEARCH 
Discussion 
 The results of this study offer a classification system based on three selling 
activity factors and six clusters or groups of regulations.  Table 3 gives the mean ratings 
for each taxonomic group across group descriptors.  The discussion provided in the 





  Customer Relationships 
Through Communication Core Selling Skills Planning 
  Mean Std. Deviation Mean Std. Deviation Mean Std. Deviation 
Cluster 1 -2.81 .278 -2.82 .230 -1.82 .477 
2 -.05 .258 -.07 .315 .10 .388 
3 -1.55 .646 -2.26 .443 -1.08 .527 
4 -.97 .558 -.59 .527 -1.55 .494 
5 -2.29 .387 -1.81 .373 1.14 .402 
6 2.55 .500 2.39 .711 2.54 .439 
Combined -1.24 1.539 -1.29 1.545 -.60 1.357 
 
 
 The results are interesting and instructive for a number of reasons.  First, six 
clusters of regulations were revealed which provide a foundation for understanding the 
interaction between regulations and selling activities in the form of an empirical 
taxonomy.  This study revealed that salespeople perceive most regulations as either 
highly restrictive (cluster 1), or have no effect at all (cluster 2) on their selling activities.  







“Highly Restrictive” Regulations (cluster 1) 
 Respondents perceived the first cluster as the most restrictive and highly negative 
group of regulations when doing their job as a salesperson.  This cluster also represents 
the largest number of regulations in one group (n=19), indicating an overall perception 
that most regulations are viewed as highly restrictive by salespeople.  A thorough 
examination of the regulations within the “highly restrictive” group reveals numerous 
specific examples that limit time with customers, prohibit gifts and entertainment, and 
other business courtesies.  This suggests that the majority of regulations enforced by the 
OIG, and PhRMA may prevent customer relationship opportunities, which by default 
restrict a salesperson’s ability to execute core selling skills and planning. 
 
“No Effect Regulations” (cluster 2) 
 The “no effect” cluster is the second largest group containing sixteen regulations 
(n=16).  Examination of specific regulations linked with “no effect” show that regulations 
designed to control firm level behavior, enforce federal and state laws such as anti-
kickback legislation, and regulations governing forms of remuneration were not 
perceived by salespeople as positive or negative with respect to their ability to perform 
selling activities.  Many of the regulations within this group are directed more toward the 
firm level and show neutral or no effect on selling activities by sales representatives.  
This is an interesting finding in two respects.  First, this suggests that a large portion of 
regulations may not be necessary considering they are viewed to have no impact on 





regulations targeted toward sales forces, and with over 27% of existing regulations 
having no effect on selling activities, a thorough needs analysis should be conducted prior 
to implementation of the regulation.  
 
“Somewhat Restrictive Regulations” (cluster 3)  
 Cluster three is unique such that the eight regulations (n=8) comprising this group 
are largely related to third party entities which limits or eliminates the ability of a 
salesperson to interact directly with their customers. For example, regulation 10 
specifically states that “relationships with formulary committee members should not 
include any remuneration from a manufacturer or its agents, nor to influence formulary 
decisions…”  In its most basic form, a “formulary” is a list of medicines that specify 
which products are approved or available for physicians to prescribe.  The formulary 
committee is a group of advisors comprised primarily of staff physicians and pharmacists 
which ultimately determine what products are placed on “formulary” (ASHP 2009).  
Therefore, it is not surprising that sales representatives view these regulations as “highly-
restrictive” since they prohibit key selling activities that can influence customer buying 
decisions.   
 In addition, many pharmaceutical firms use third-party vendors to conduct 
promotional speaking events, educational symposia, and physician speaker events.  
However, rules like regulation number six specifically state; “the manufacturer should 
have no control over the speaker or content of an educational presentation.”  This form of 
regulation prohibits the sales person from speaking directly with a customer who they 





salesperson is unable to build customer relationships, use his/her core selling skills, and 
plan.  This finding indicates that salespeople perceive certain regulations as somewhat 
restrictive when dealing with entities other than their direct prospects.   
 
“Restrictive in Office Regulations” (cluster 4) 
 Overall, the regulations grouped in the “restrictive in office” cluster (n=7) are all 
perceived to have a negative impact on selling activities.  However, unlike the “no effect” 
cluster which was highly negative in all categories, this cluster was slightly negative in 
customer relationships through communication, and core selling skills.  On the other 
hand, planning was ranked highly negative in this category.  Inspection of the seven 
regulations linked with the “restrictive in office” cluster suggests that planning activities 
are perhaps more strategic and therefore experience a greater negative impact than other 
more direct customer activities such as relationship building and core selling skills.   
 Historically, giving inexpensive “reminder” promotional items (pens, note pads, 
mugs, etc. with company logos or product names) to potential and existing customers was 
a common selling activity for pharmaceutical representatives.  This practice was believed 
to enhance a sales person’s ability to “gain access” to new customers, search out new 
leads, and conduct targeting activities.  For example, experienced sales people would use 
a coffee mug that contained their product name and logo as a way to get a customer’s 
attention and to initiate product or service discussions. 
 Regulation 55, cluster 4, currently prohibits the practice of providing items for 
healthcare professionals’ use that do not advance disease or treatment education, 





conducting planning activities such as pre-call planning, and searching out new leads.  
However, it was perceived to have minimal negative effect on activities such as listening 
to customers or handling customer objections.  This discovery demonstrates the different 
effects a regulation can have depending on the specific selling activity being conducted.      
  
“Bad with Customer / Good in Office Regulations” (cluster 5) 
 The “bad with customer / good in office” cluster (n=5) produced a unique 
distinction suggesting this group of regulations has an opposite effect on selling activities 
conducted in front of customers ("customer relationships through communication" and 
"core selling skills", -2.29 and -1.81 respectively) versus those conducted away from 
customers (“planning”, 1.14).  Inspection of the five regulations in the “bad with 
customer / good in office” cluster reveals that four of the regulations (regulations 30, 34, 
36, and 54) limit and/or prohibit providing meals, financial support, or other business 
courtesies unless it is facilitated through a third-party entity such as conference sponsors, 
event planners, or academic or training institutions.  In addition, regulation 23 states; 
“occasional meals may be offered as a business courtesy to healthcare professionals 
(including members of their staff) attending sales/marketing presentations as long as the 
presentations provide scientific or educational value”.  
 Each of the regulations in “bad with customer / good in office” contain a 
“condition” statement (i.e., as long as; only if; or except that) that appears to separate 
selling activities conducted in the customer’s presence (“customer relationships through 
communication" and "core selling skills") from those conducted away from customers 





on selling activities that are conducted while face-to-face with customers versus those 
conducted outside the presence of a customer.  This finding, the fact that certain 
regulations can have both positive and negative effects on selling activities, further 
supports the value of a classification system such as the taxonomy presented here.   
 
“Helpful Regulations” (cluster 6) 
 After examining the four regulations (n=4) found within the “helpful” group, we 
observed that each of the regulations supported activities such as providing customers 
with occasional meals, the ability to include staff members in the activity, and the 
requirement that customers must sign a contract describing the nature of their 
commitment and services to be provided.  If a regulation makes it easy to gain access to a 
customer, and facilitates relationship building such as providing a meal, it is not 
surprising that sales representatives would find these regulations as “helpful”.  What this 
suggests is that sales organizations may benefit by providing their salespeople with 
regulations describing what they "can" do rather than what they "cannot" do.  Each of the 
four regulations within this group specifically states examples of promotional activities 
that are allowed.  Of note, these are the only four regulations that describe what is 
allowed versus what is prohibited.  The usefulness of these regulations was viewed as 
positive by all respondents indicating a wide acceptance among the entire sales force. 
  
Taxonomy in Research 
 This article defines the process and reports the findings of a comprehensive 





basis of the entire project, however, is that sales forces continue to spend billions of 
dollars annually to support thousands of direct salespeople and their activities, without 
any understanding of the interrelated phenomena that regulations impose on selling 
activities.  Clearly, the growing number of regulations placed upon sales forces indicates 
a critical transformation in the business setting that affects the discipline of selling and 
sales management.  Taxonomies are consistently used in business research and are 
fundamental in classifying and learning about phenomena.  Until now, conceptualization 
of how regulations affect selling activities has not been empirically studied.  The results 
of this study and the taxonomy presented here offer numerous insights into organizing 
complex sets of regulations and selling activities.     
 The taxonomy produced in this study is based on three (3) factors and six (6) 
clusters or groups.  Of particular interest, the results of the factor analysis revealed three 
distinct groups of selling activities; (1) customer relationships through communication, 
(2) core selling skills, and (3) planning.  They seemingly resemble the sales 
communication behaviors measures (“get”, “give”, and “use”) adapted from Reid, 
Minton, and Plank (1996), however by examining the selling activities in the presence of 
regulations, our factor analysis effectually combined “questioning”, “listening”, 
“charismatic presentations”, and “working well with people” into its own category 
renamed “customer relationships through communication”.  The second new group 
(factor) that was identified includes a combination of “customer participation”, “getting 
customers to see product benefits”, “meeting customer needs”, and “ability to handle 
objections”.  This new category represents “core selling skills” that engage customers in 





activities conducted away from customers such as “pre-call planning”, “designing a sales 
plan”, and “conducting targeting activities”.   From a selling perspective, it is quite 
interesting to learn that the presence of regulations changed the sales communication 
behavior categories into different groupings effectually describing new categories of 
selling activities. 
 The taxonomy of regulations presented herein provides a fascinating picture of 
the impact they can have on selling activities.  Although much has been written about the 
existence of regulations in business, our study is the first to specifically investigate and 
supply strong support through an empirically derived taxonomy how certain regulations 
affect some selling activities more than others.  One of our key findings indicates that the 
perceived effects of regulations are very “cleanly” loaded into respective categories 
(clusters) by respondents.  In other words, there is a very high degree of homogeneity 
within clusters.  For example, regulations that prohibit gift giving, entertainment, 
business courtesies, and other relationship building activities loaded exclusively into the 
“highly restrictive” (very negative) cluster of regulations by all respondents with no 
respondent ratings found in other clusters.  The same high degree of homogeneity was 
observed in the “helpful” (very positive) cluster of regulations whereby all respondents 
perceived the ability to “provide meals to customers”, “provide meals to staff”, and 
“written contracts with customers” as positively affecting their ability to do their job as a 
sales person.  This finding suggests that pharmaceutical representatives are very clear and 
consistent regarding how regulations affect their selling activities.  This could be a 
reflection of the level of regulatory training they receive or possibly the clear explicit 





 By using these categories, future researchers can add generalizability to their 
findings on the impact of regulations allowing comparisons across industries, regulating 
entities, and regulations themselves.  It is hoped that the tool created here will spur 
research into the interaction between regulation and sales. 
 
Managerial Implications 
 In terms of practical application, the taxonomy developed is this study could help 
a manager develop their own companies’ approach to regulations and ascertain the 
impact different regulations have on their sales force activities.  Furthermore, the value in 
our taxonomy lies in its potential to provide managerial insight and direction by isolating 
groups of regulations with predictive significance regardless of industry. 
 Sales managers whose industries are exploring the idea of tighter regulatory 
controls, or whose firms have not considered the impact regulations might have on their 
sales and marketing activities, can use this taxonomy to develop alternative selling 
strategies to enhance customer impact.  For example, by identifying whether salespeople 
perceive a regulation as “highly restrictive”, “helpful”, or having “no effect” on their day-
to-day activities, a manager can tailor training and education for his/her sales force in 
order to provide the skills necessary to better serve their customers as well as comply 
with the regulation(s). 
 From a marketing perspective, using the known clusters of regulations, 
practitioners can verify whether the promotional materials and activities they believe are 
vital to their sales team fit into one of the six clusters, or not.  Based on the cluster, 





resources and supplies, or develop different strategies to accommodate the growing 
number of regulations with which they must comply.  In other words, are there certain 
strategies that allow them to overcome issues related to regulations and their selling 
activities better than others?   
 For the sales manager, this study may be useful in the identification of skills and 
behaviors associated with highly effective sales representatives in a highly regulated 
environment.  For example, a successful pharmaceutical representative that relies heavily 
on building customer relationships through communication as their primary selling skill 
may find the regulation that permits occasional meals at meetings, so long as the 
presentation provides scientific value, as highly restrictive.  From their perspective, they 
prefer to have lunch with a customer to build relationships and rapport and believe that 
conducting a scientific presentation would negatively impact their interaction.  Therefore, 
they may decide to not provide occasional meals at all and exclude customers that will 
only meet over lunch.  On the other hand, another successful pharmaceutical 
representative has found that conducting scientific presentations at lunch meetings is an 
effective way to search out new leads, target customers, and design their sales plan.  For 
those reasons, the second representative routinely meets new customers over lunch 
meetings while sharing scientific product information.  This example implies the need for 
further training among affected sales representatives and managers based upon identified 
best practices. 
 Finally, from the taxonomy developed in this study, managers can sort their own 






taxonomy, they can determine new ways to approach customers and develop alternative 
selling strategies. 
 
Limitations and Future Research Opportunities 
 Before future research opportunities are noted, several limitations should be 
raised.  First, the sample in this study included sales representatives from one firm within 
the pharmaceutical industry.  Although pharmaceuticals is known to be one of the most 
regulated industries today, industries such as banking, real estate, telecommunications, 
and tobacco would also be appealing and meaningful for other investigators to test our 
taxonomical methodology.  We acknowledge this as a "limitation", however this was a 
mindful strategic choice in designing the research. 
 An inherent limitation of the taxonomic process includes several subjective and 
sequential decisions related to data analysis.  We recognize that strong conceptual 
support is necessary to deal with issues such as what variables to include, why groups 
exist in the first place, and determining the number of clusters in the final solution.  
Additionally, analysis of this type of data required several different analytical 
approaches; however the present study relies heavily on the use of exploratory factor 
analysis (EFA), and two-step cluster analysis.  Though each step of the analysis was 
carefully specified and reviewed by two additional researchers, applying a different 
sequence of analytical steps might deduce the data in a slightly different way.  We 
recognize that problems are inherent in both methods which is acknowledged. 
 Future research directions are several.  Marketing and sales scholars can play an 





about how to effectively sell in an ever increasing regulated environment have been 
guided by “reaction” and “intuition” rather than by marketing/sales experts and scholars.  
Research in the area of sales strategy development is needed to guide these decisions 
which often have huge financial consequences.  Building upon an initial taxonomical 
scheme, as described here, can help develop theoretical strategy frameworks for future 
research in the areas of relational communication, and interpersonal influencing in the 
context of selling.  Moreover, further research could explore which regulations impact 
customer commitment and trust (Morgan and Hunt 1994).  
 There is a pressing need for better understanding of the costs associated with 
regulations placed on sales organizations.  Many companies are unaware of the costs to 
monitor, enforce, and implement regulations within their organizations and how those 
costs impact overall firm performance.  It would be interesting to extend this regulatory 
taxonomy to include demographic data, longitudinal performance outcomes, and cost 
measures.  With large quantities of complex and vague regulations with which sales 
people must comply, our research underscores the need to execute fiscal analyses on the 
major clusters of regulations to examine whether a regulation’s intended benefits surpass 
its costs.  The research presented here provide a timely context for further research on the 
interaction between regulations and selling behaviors, which seem to be central to the 
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Complete Typology for Source of Regulations 
 
  Federal Regulations 
1.  Office of Inspector General (OIG)   
2.  Federal Trade Commission (FTC) 
3.  Division of Drug Marketing and Communication (DDMAC) 
 
State Regulations (including District of Columbia) 
1.  Massachusetts   4.  Maine  7. Nevada  
2.  California   5.  Vermont   
3.  D.C.    6.  South Dakota 
  
Industry Regulations 




6 major pharmaceutical firms will be used in the study.  Names are blinded to the reader to 












Comprehensive list of the 94 “core” regulations 
 
ID Guideline / Regulation 
1 Pharmaceutical manufacturers must develop and distribute 
written standards of conduct, as well as written policies, 
procedures and protocols that verbalize the company’s 
commitment to compliance. 
2 Pharmaceutical manufacturers must include adherence to 
the compliance program as an element in evaluating 
management and employees. 
3 Pharmaceutical manufacturers must address specific areas 
of potential fraud and abuse, such as the reporting of 
pricing and rebate information to the federal health care 
programs, and sales and marketing practices, within their 
policies and procedures. 
4 Pharmaceutical manufacturers must designate a 
compliance officer other appropriate bodies (e.g., a 
corporate compliance committee) charged with the 
responsibility for developing, operating, and monitoring the 
compliance program, and with authority to report directly to 
the board of directors and/or the president or CEO. 
5 Pharmaceutical manufacturers must develop and 
implement regular, effective education and training 
programs for all affected employees. 
6 Pharmaceutical manufacturers must create and maintain an 
effective line of communication between the compliance 
officer and all employees. 
7 Pharmaceutical manufacturers must develop a process 
(such as a hotline or other reporting system) to receive 
complaints or questions. 
8 Pharmaceutical manufacturers must adopt procedures to 
protect the anonymity of complaints and to protect 
“whistleblowers” from retaliation. 
9 Pharmaceutical manufacturers must use audits and/or other 
risk evaluation techniques to monitor compliance, identify 






10 Pharmaceutical manufacturers must develop policies and 
procedures for addressing the non-employment or retention 
of individuals or entities excluded from participation in 
federal health care programs. 
11 Pharmaceutical manufacturers must enforce appropriate 
disciplinary action against employees or contractors who 
have violated company policies and procedures and/or 
applicable federal health care program requirements. 
12 Pharmaceutical manufacturers must develop policies and 
procedures for the investigation of identified instances of 
noncompliance or misconduct. 
13 Policies and procedures for the investigation of identified 
instances of noncompliance or misconduct must include 
directions regarding the prompt and proper response to 
detected offenses, such as the initiation of appropriate 
corrective action and preventive measures and processes 
to report the offense to relevant authorities in appropriate 
circumstances. 
14 Every pharmaceutical manufacturer is required to develop 
and distribute written compliance standards, procedures, 
and practices that guide the company and the conduct of its 
employees in day-to-day operations. 
15 Policies and procedures that guide the company and the 
conduct of its employees in day-to-day operations must be 
developed under the direction and supervision of the 
compliance officer, the compliance committee, and 
operational managers. 
16 At a minimum, the policies and procedures must be 
provided to all employees who are affected by these 
policies, and to any agents or contractors who may furnish 
services that impact federal health care programs (e.g., 
contractors involved in the co-promotion of a 
manufacturer’s products. 
17 Pharmaceutical manufacturers must develop a general 
corporate statement of ethical and compliance principles 
that will guide the company’s operations. 
18 Pharmaceutical manufacturers must develop of code of 
conduct statement of principles to include the company’s 
expectations of commitment to compliance by 
management, employees, and agents, and should 
summarize broad ethical and legal principles under which 
the company must operate. 
19 Pharmaceutical manufacturers must include their board of 
directors, CEO, president, members of senior management, 
and other personnel from various levels of the 





the compliance program, especially the code of conduct. 
20 Pharmaceutical manufacturers are responsible for ensuring 
the integrity of data they generate that is used for 
government reimbursement purposes. 
21 Pharmaceutical manufacturers are prohibited to offer 
payments (in any form, whether the payments are direct or 
indirect) purposefully to induce or reward the referral or 
generation of federal health care business.  (Anti-kickback 
statute) 
22 Pharmaceutical manufacturers are prohibited to offer 
anything of value in return for purchasing, leasing, ordering, 
or arranging for or recommending the purchase, lease, or 
ordering of any item or service reimbursable in whole or 
part by a federal health care program. 
23 Pharmaceutical manufacturers are prohibited to solicit or 
accept remuneration for referrals. 
24 Pharmaceutical manufacturers must identify any 
remunerative relationship between itself (or its 
representatives) and persons or entities in a position to 
generate federal health care business for the manufacturer 
directly or indirectly. 
25 Pharmaceutical manufacturers are prohibited from 
arrangements or practices that have a potential to interfere 
with, or skew, clinical decision-making. 
26 Pharmaceutical manufacturers are prohibited from 
arrangements or practices that have a potential to 
undermine the clinical integrity of a formulary process. 
27 Pharmaceutical manufacturers are prohibited from 
arrangements or practices that involve providing information 
to decision-makers, prescribers, or patients that does not 
include complete and accurate information (not misleading). 
28 Pharmaceutical manufacturers are prohibited from 
arrangements or practices that have a potential to increase 
costs to the federal health care programs, beneficiaries, or 
enrollees. 
29 Pharmaceutical manufacturers are prohibited from 
arrangements or practices that have the potential to be a 
disguised discount to circumvent the Medicaid Rebate 
Program Best Price calculation. 
30 Pharmaceutical manufacturers are prohibited from 
arrangements or practices that have a potential to increase 
the risk of overutilization or inappropriate utilization. 
31 Pharmaceutical manufacturers are prohibited from 
arrangements or practices that raise patient safety or 
quality of care concerns. 





providing any remuneration to a direct purchaser (e.g., 
hospitals, nursing homes, pharmacies, some physicians), 
as well as indirect purchasers (e.g., health plans) that is 
expressly or impliedly related to a sale. 
33 Pharmaceutical manufacturers are prohibited from hiding 
de facto pricing concessions to other purchasers to avoid 
passing on the same discount to others. 
34 Pharmaceutical manufacturers are prohibited from offering 
services that have no substantial independent value to the 
purchaser (e.g., billing assistance tailored to the purchase 
products, reimbursement consultation, and other programs 
specifically tied to support of the purchased product). 
35 Pharmaceutical manufacturers are prohibited from offering 
funding (grants) that are conditioned, in whole or in part, on 
the purchase of products. 
36 Pharmaceutical manufacturers are prohibited from 
influencing the substance of an educational program or the 
presenter. 
37 Pharmaceutical manufacturers must separate their grant 
making functions from their sales and marketing functions. 
38 Third-party scientific and educational conferences or 
professional meetings are permitted provided; (a) the 
gathering is primarily dedicated, in both time and effort, to 
promoting objective scientific and educational activities and 
discourse, (b) the main incentive for bringing attendees 
together is to further their knowledge on the topic(s) being 
presented. 
39 The pharmaceutical manufacturer should have no control 
over the speaker or content of any educational 
presentation. 
40 Items intended for the personal benefit of healthcare 
professionals (such as floral arrangements, artwork, music 
CDs or tickets to a sporting event) are prohibited. 
41 Payments in cash or cash equivalents (such as gift 
certificates) are prohibited. 
42 Pharmaceutical manufacturers are prohibited from offering 
payments to cover the costs of “converting” from a 
competitor’s product. 
43 Pharmaceutical manufacturers are prohibited from 
providing selective offers of remuneration (i.e., offers made 
to some but not all purchasers). 
44 Pharmaceutical manufacturers are prohibited from offering 
any remuneration directly or indirectly to person(s) in a 
position to influence formulary decisions related to the 
manufacturer’s products. 





lump sum payments for inclusion in a formulary or for 
exclusive or restricted formulary status. 
46 Pharmaceutical manufacturers are prohibited from 
providing anything of value to a physician who might 
prescribe the manufacturer’s product. 
47 Pharmaceutical manufacturers are prohibited from 
providing switching arrangements that involve offering 
physicians cash payments or other benefits each time a 
patient’s prescription is changed to the manufacturer’s 
product from a competing product. 
48 Pharmaceutical manufacturers are prohibited from 
compensating physicians as “consultants” when they are 
expected to attend meetings or conferences primarily in a 
passive capacity. 
49 Pharmaceutical manufacturers are prohibited from 
compensating physicians for services connected directly or 
indirectly to a manufacturer’s marketing and sales activities, 
such as speaking, certain research, or preceptor or 
“shadowing” services. 
50 Providing items for healthcare professional’ use that do not 
advance disease or treatment education, even if they are 
practice-related items of minimal value (such as pens, note 
pads, mugs and similar “reminder” items with company or 
product logos) are prohibited. 
51 Pharmaceutical manufacturers are prohibited from 
compensating physicians for time spent listening to sales 
representatives market pharmaceutical products. 
52 Pharmaceutical manufacturers are prohibited from 
compensating physicians for time spent accessing web 
sites to view or listen to marketing information or perform 
“research”. 
53 Pharmaceutical manufacturers are prohibited from 
providing entertainment, recreation, travel, meals, or other 
benefits in association with information or marketing 
presentations. 
54 Pharmaceutical manufacturers are prohibited from offering 
gifts, gratuities, and other business courtesies. 
55 Pharmaceutical manufacturers and their representatives 
are prohibited from using activities that channel improper 
remuneration to physicians or others in position to generate 
business for the manufacturer or to influence or control the 
content of a program. 
56 Modest, occasional meals are permitted as long as they are 
offered in the appropriate circumstances and venues. 
57 Companies are required to separate its CME grant-making 





58 Pharmaceutical manufacturers are required to institute and 
implement corrective action and disciplinary policies 
applicable to sales agents who engage in improper 
marketing. 
59 Pharmaceutical manufacturers are required to avail itself of 
the advisory opinion process if it has questions about 
particular practices used by its sales force. 
60 Pharmaceutical manufacturers are required to establish an 
effective system for tracking, compiling, and reviewing 
information about sales force activities, including if 
appropriate, random spot checking. 
61 Pharmaceutical manufacturers are required to provide 
accurate and not misleading promotional materials when 
interacting with healthcare professionals. 
62 Promotional materials provided to healthcare professionals 
must only make claims about a product when properly 
substantiated. 
63 Promotional materials provided to healthcare professionals 
must reflect the balance between risks and benefits. 
64 Companies are prohibited from providing meals directly at 
CME events, except that a CME provider at its own 
discretion may apply the financial support provided by a 
company for a CME event to provide meals for all 
participants. 
65 Any meals offered in connection with informational 
presentations made by field sales representatives or their 
immediate managers should also be limited to in-office or 
in-hospital settings. 
66 Inclusion of a healthcare professional’s spouse or other 
guest in a meal accompanying an informational 
presentation made by or on behalf of a company is 
prohibited. 
67 It is prohibited for companies or agents of the companies to 
provide entertainment or recreational items, such as tickets 
to the theater or sporting events, sporting equipment, or 
leisure or vacation trips, to any healthcare professional who 
in not a salaried employee of the company. 
68 It is required that companies adopt a Comprehensive 
Compliance Program (CCP) that is in accordance with both 
the OIG Guidance and the most recent version of the 
PhRMA Code. 
69 Pharmaceutical companies are required to annually set a 
spend limit on gift s and 
meals to California HCPs and publicly post that limit, along 
with a copy of its CCP and certification of compliance. 





sell or market a drug, medicine, chemical, device or 
appliance in the state must file annual submissions with the 
Nevada Board of Pharmacy confirming compliance with the 
law’s training, investigation and auditing requirements. 
71 The law requires manufacturers and wholesalers to adopt a 
Marketing Code of Conduct setting forth the company’s 
“practices and standards that govern the marketing and 
sale of its products. 
72 Companies are required to disclose the value, nature and 
purpose of gift s provided to HCPs 
73 Requires companies to adopt and certify compliance with 
the Massachusetts Department of Health’s Marketing Code 
of Conduct provisions. 
74 limits the ability of PBMs to switch South Dakota residents’ 
prescription drugs by allowing higher-priced drugs to be 
substituted for lower-priced prescribed drugs only for 
medical reasons that benefit the covered individual 
75 Sales representatives are required to obtain a license to 
“practice pharmaceutical detailing” in the District while 
certifying compliance with a marketing code of ethics. 
76 Sales representatives who interact with District of Columbia 
HCPs must keep detailed records about those interactions. 
These records include not only the contact information for 
the HCP or the employee or representative of the HCP, but 
also details about the types of promotional materials left 
with the individual and whether any sample products were 
provided. 
77 Reporting of expenses related to company-sponsored 
educational and informational sessions, including food, 
entertainment, travel, gifts valued at $25 or more. 
78 The provision of gifts by pharmaceutical and medical device 
manufacturers to healthcare professionals is prohibited. 
79 All sales and marketing employees are required to 
successfully pass the company developed pharmaceutical 
promotional guidelines exam. 
80 All sales and marketing employees are prohibited to 
participate in customer meetings when a scientific manager 
(liaison) is present. 
81 Sales representatives must receive prior approval from their 
immediate supervisor for all promotional expenditures. 
82 It is prohibited for sales representatives to “steer” physician 
speaker content or presentation materials.  
83 All speaker events are prohibited. 
84 Providing entertainment, meals, and gifts is prohibited by all 
sales and marketing personnel. 





scientific/educational meetings conducted by medical affairs 
or scientific liaisons. 
86 Sales representatives are prohibited from altering 
promotional materials in any way (e.g., using yellow 
highlighters, circling certain items of interest, etc.). 
87 Sales representatives are prohibited to use any “non-
approved” promotional information items (e.g., books, 
newspaper articles, articles printed from the web, etc.) 
88 Sales representatives must provide an approved 
promotional proof source at every customer interaction. 
89 Sales representatives are prohibited from offering “take-
out” meals to customers. 
90 Sales representatives are prohibited from responding to 
customer questions not related to their own product (e.g., 
competitive product questions). 
91 Sales representatives are prohibited to discuss non-
approved (FDA) indications for their products.  Even if 
asked by the physician. 
92 Sales representatives are prohibited from using competitive 
product package inserts to make product comparisons. 
93 If a sales representatives is a currently licensed medical 
professional (e.g., R.N., Paramedic, M.D., etc.) it is 
prohibited to exercise the skills by which you are licensed 
while actively working for the company.  In other words, it is 
prohibited to offer medical advice, care, etc. while working 
as a representative of the company. 
94 Sales representatives are prohibited from participating in 
“preceptorships” or “shadowing” events with physicians or 








REGULATIONS:   
OFFICE OF INSPECTOR GENERAL (OIG), HHS;  
THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF 
AMERICA (PhRMA) 
=============================================================== 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
Agency:  Office of Inspector General (OIG), HHS 
OIG Compliance Program Guidance for Pharmaceutical Manufacturers 
Background 
Preventing and reducing fraud and abuse in federal health care programs is a major 
initiative of the OIG (Federal Register 2003).  The OIG states (2003, p. 23731), “The 
purpose of the compliance program guidance is to encourage the use of internal controls 





Guidelines/ regulations for pharmaceutical manufacturers: 
 
A. Title:  The Basic Compliance Elements 
a. The development and distribution of written standards of conduct, written 
policies, procedures and protocols that verbalize the company’s commitment to 
compliance. 
b. Designation of a compliance officer. 
c. Development and implementation of regular, effective education and training 
programs. 
d. The creation and maintenance of an effective line of communication between the 
compliance officer and all employees. 





f. The development of policies and procedures for the investigation of identified 
instances of noncompliance or misconduct. 
 
B. Title:  Integrity of Data Used to Establish or Determine Government Reimbursement 
Description:  “Many federal and state health care programs establish or ultimately 
determine reimbursement rates for pharmaceuticals, either prospectively or 
retrospectively, using price and sales data directly or indirectly furnished by 
pharmaceutical manufacturers.  The government sets reimbursement with the 
expectation that the data provided are complete and accurate.” 
Guideline:  The knowing submission of false, fraudulent, or misleading 
information is actionable.  Under the False Claims Act, a pharmaceutical 
manufacturer may be liable if government reimbursement information is not 
reported completely and accurately.  Manufacturers’ reported prices should 
accurately take into account price reductions, cash discounts, free goods 
contingent on a purchase agreement, rebates, up-front payment, coupons goods in 
kind, free or reduced-price services, grants, or other price concessions or similar 
benefits offered to some or all purchases. 
Guideline summary:  Pharmaceutical manufacturers are responsible for ensuring 
the integrity of data they generate that is used for government reimbursement 
purposes. 
C. Title:  Kickbacks and Other Illegal Remuneration 
Description:  “The anti-kickback stature is a criminal prohibition against 
payments (in any form, whether the payments are direct or indirect) made 
purposefully to induce or reward the referral or generation of federal health care 
business.” 
Guideline:  The offer or payment of anything of value for patient referrals, but 
also the offer or payment of anything of value in return for purchasing, leasing, 
ordering, or arranging for or recommending the purchase, lease, or ordering of 
any item or service reimbursable in whole or part by a federal health care 
program, is prohibited. 
Guideline summary:  A manufacturer should identify any remunerative 
relationship between itself (and its representatives) and persons or entities in a 






 i. The arrangement or practice shall not have a potential to interfere with, 
or skew, clinical decision-making. 
ii. The arrangement or practice shall not undermine the clinical integrity of 
a formulary process. 
 iii. If the arrangement or practice involves providing information to 
decision-makers, prescribers, or patients, the information must be 
complete, accurate and not misleading. 
 iv. The arrangement or practice shall not have a potential to increase costs 
to the federal health care programs, beneficiaries, or enrollees. 
 v. The arrangement or practice shall not have the potential to be disguised 
as a discount to circumvent the Medicaid Rebate Program Best Price 
calculation. 
 vi. The arrangement or practice shall not have a potential to increase the 
risk of overutilization or inappropriate utilization. 
 vii. The arrangement or practice shall not raise patient safety or quality of 
care concerns. 
D. Title:  Relationships with Purchases and their agents 
Description:  “Pharmaceutical manufacturers offer purchasers a variety of price 
concessions and other remuneration to induce the purchase of their products.  
Inducements offered to purchasers potentially implicate the anti-kickback stature 
if the purchased products are reimbursable to the purchase, in whole or in part, 
directly or indirectly, by any of the federal health care programs.  Any 
remuneration from a manufacturer provided to a purchaser that is expressly or 
impliedly related to a sale potentially implicates the anti-kickback stature and 
should be carefully reviewed.” 
Guidelines: 
 i. Product Support Services:  A manufacturer is prohibited, under the anti-
kickback statute, from coupling a service that has no independent value in 
tandem with another service or program that confers a benefit on a 
referring provider.  “For example, the anti-kickback stature would be 
implicated if a manufacturer were to couple a reimbursement support 
service with a promise that a purchaser will pay for ordered products only 






 ii. Educational Grants:  Pharmaceutical manufacturers sometimes provide 
grant funding for a wide range of educational activities.  Funding that is 
conditioned, in whole or in part, on the purchase of product implicates the 
statute, even if the educational or research purpose is legitimate.   
 
Therefore, to reduce the risks that a grant program is used improperly to 
induce or reward product purchases or to market product inappropriately, 
manufacturers should separate their grant making functions from their 
sales and marketing functions.  Sales and marketing functions are 
prohibited from providing grants. 
 
 Manufacturers must establish objective criteria for making grants that do 
not take into account the volume or value of purchases made by, or 
anticipated from, the grant recipient. 
 
 The manufacturer should have no control over the speaker or content of 
the educational presentation. 
 
 Compliance with such procedures should be documented and regularly 
monitored. 
 
 iii. Research Funding:  Manufacturers often contract with purchasers of 
their products to conduct research activities on behalf of the manufacturer 
on a fee-for-service basis.  Manufacturers should develop contracting 
procedures that clearly separate the awarding of research contracts from 
marketing. 
 
 iv. Other remuneration to purchasers:  Any remuneration from a 
manufacturer provided to a purchaser that is expressly or impliedly related 
to a sale may implicate the anti-kickback stature and should be carefully 
reviewed. 
 
a. Any payments to cover the costs of “converting” from a 
competitor’s product are prohibited. 
 
b. Selective offers of remuneration (i.e., offers made to some but 
not all purchasers) may increase potential risk if the selection 
criteria relate directly or indirectly to the volume or value of 
business generate, are therefore prohibited. 
 
c. Relationships with formulary committee members should not 
include any remuneration from a manufacturer or its agents 







d. Formulary placement payments for inclusion in a formulary or 
for exclusive or restricted formulary status are prohibited. 
 
e. Relationships with physicians and other persons and entities in a 
position to make or influence referrals should not influence the 
referral, ordering, or prescribing of the manufacturers’’ products. 
 
f. If goods or services provided by the manufacturer eliminate an 
expense that the physician would have otherwise incurred (i.e., 
have independent value to the physician), or if items or services are 
sold to a physician at less than their fair market value, the 
arrangement is prohibited. 
 
g. “Switching” arrangements involve pharmaceutical 
manufacturers offering physicians or others cash payments or other 
benefits each time a patient’s prescription is changed to the 
manufacturer’s product from a competing product, is prohibited. 
 
h. Consulting and advisory payments whereby pharmaceutical 
manufacturers frequently engage physicians and other health care 
professionals to furnish personal services as consultants or advisers 
to the manufactures must be at fair market value to small numbers 
of physicians for bona fide consulting or advisory services. 
 
i. Compensating physicians for services directly or indirectly 
related to sales and marketing activities such as speaking, certain 
research, or preceptor or “shadowing” services is prohibited. 
 
j. Payments for detailing (i.e., compensating physicians for time 
spent listening to sales representatives market pharmaceutical 
products), is prohibited. 
 
k. Payments for time spent accessing web sites to view or listen to 
marketing information or perform “research” is prohibited. 
 
 
v. Business courtesies and Other Gratuities:  Pharmaceutical companies 
and their employees and agents often engage in a number of others 
arrangements that offer benefits, directly or indirectly, to physicians or 
others in a position to make or influence referrals.   
 
a. Entertainment, recreation, travel, meals, or other benefits in 













THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 
(PhRMA) 
Code on Interactions with Healthcare Professionals 
Background 
The Pharmaceutical Manufacturers Association was founded in 1958. Its name was 
changed to the Pharmaceutical Research and Manufacturers of America in 1994.    
“Ethical relationships with healthcare professionals are critical to our mission of helping 
patients by developing and marketing new medicines.  This document focuses on 
interactions with healthcare professionals that relate to the marketing of products.  This 
Code is to reinforce our intention that our interactions with healthcare professionals are 
professional exchanges designed to benefit patients and to enhance the practice of 




Code/ guidelines/ regulations for pharmaceutical manufacturers: 
 
1. “Basis of Interactions:  Promotional materials provided to healthcare professionals by or 
on behalf of a company should:  (a) be accurate and not misleading; (b) make claims 
about a product only when properly substantiated; (c) reflect the balance between risks 
and benefits; and (d) be consistent with all other Food and Drug Administration (FDA) 
requirements governing such communications.” 
 
2. Informational Presentations by Pharmaceutical Company Representatives and 
Accompanying Meals 
a. It is appropriate for occasional meals to be offered as a business courtesy to the 
healthcare professionals as well as members of their staff attending presentations, 
so long as the presentations provide scientific or education value and the meals 
(a) are modest as judged by local standards; (b) are not part of an entertainment 
or recreational event; and (c) are provided in a manner conducive to 
informational communication. 
b. Any such meals offered in connection with informational presentations made by 
field sales representatives or their immediate managers should also be limited to 
in-office or in-hospital settings. 
c. Inclusion of a healthcare professional’s spouse or other guest in a meal 
accompanying an informational presentation made by or on behalf of a company 





d. Offering “take-out” meals or meals to be eaten without a company representative 
being present in not appropriate. 
 
3. Prohibition on Entertainment and Recreation 
a. Companies should not provide any entertainment or recreational items. 
i. Examples include but not limited to:  tickets to the theater or sporting 
events, sporting equipment, or leisure or vacation trips. 
ii. Such entertainment or recreational benefits should not be offered, 
regardless of (1) the value of the items; (2) whether the company engages 
the healthcare professional as a speaker or consultant, or (3) whether the 
entertainment or recreation is secondary to an educational purpose. 
 
4. Pharmaceutical Company Support for Continuing Medical Education 
a. Giving of any subsidy directly to a healthcare professional by a company is 
prohibited.   
b. Any financial support should be given to the CME provider, which, in turn, can 
use the money to reduce the overall CME registration fee for all participants. 
c. The company is prohibited to provide any advice or guidance to the CME 
provider, even if asked by the provider, regarding the content or faculty for a 
particularly CME program funded by the company. 
d. Financial support is prohibited for the costs of travel, lodging, or other personal 
expenses of non-faculty healthcare professionals attending CME. 
e. Funding should not be offered to compensate for the time spent by healthcare 
professionals participating in the CME event. 
f. A company should not provide meals directly at CME events, except that a CME 
provider at its own discretion may apply the financial support provided by a 
company for CME event to provide meals for all participants. 
 
5. Pharmaceutical Company Support for Third-Party Educational or Professional Meetings 
a. Any subsidy or financial support for professional meetings may not be provided 
to a healthcare professional. 
b. Financial support for professional meetings should be given directly to the 
conference’s sponsor, which, in turn, can use the money to reduce the overall 
conference registration fee for all attendees. 
c. When companies underwrite medical conferences or meetings other than their 
own, responsibility for and control over the selection of content, faculty, 
educational methods, materials, and venue belongs to the organizers of the 
conference and may not be influence by the sponsoring company. 




a. Consulting agreements are prohibited to serve as either inducements or rewards 
for prescribing or recommending a particular medicine or course of treatment. 
b. A written contract must specify the nature of the consulting services to be 
provided and the basis for payment of those services. 
c. A legitimate need for the consulting services must be clearly identified in 






d. The criteria for selecting consultants must be directly related to the identified 
purpose and the persons responsible for selecting the consultants have the 
expertise necessary to evaluate whether the particular healthcare professionals 
meet those criteria. 
e. It is required that the number of healthcare professionals retained is not greater 
than the number reasonably necessary to achieve the identified purpose. 
f. The retaining company must maintain records concerning and makes appropriate 
use of the services provided by consultants. 
g. The venue and circumstances of any meeting with consultants are conducive to 
the consulting services and activities related to the services are the primary focus 
of the meeting; specifically, resorts are not appropriate venues. 
h. Companies are prohibited to provide recreational or entertainment events in 
conjunction with consultant/ educational meetings. 
i. It is prohibited to pay honoraria or travel or lodging expenses to non-faculty and 
non-consultant healthcare professional attendees at company-sponsored 
meetings, including attendees who participate in interactive sessions. 
 
7. Speaker Programs and Speaker Training Meetings 
a. Company decisions regarding the selection or retention of healthcare 
professionals as speakers should be made based on defined criteria such as 
general medical expertise and reputation. 
b. Each company should cap the total amount of annual compensation it will pay to 
an individual healthcare professional in connection with all speaking 
arrangements. 
c. Each company should develop policies addressing the appropriate use of 
speakers, including utilization of speakers after training and the appropriate 
number of engagements for any particular speaker over time. 
d. Speakers and their materials must clearly identify the company that is sponsoring 
the presentation. 
e. Companies must monitor speaker programs for compliance with FDA regulatory 
requirements for communications on behalf of the company about its medicines. 
 
8. Healthcare Professionals Who Are Members of Committees That Set Formularies of 
Develop Clinical Practice Guidelines 
a. Companies must require any healthcare professional who is a member of a 
committee that sets formularies or develops clinical guidelines and also serves as 
a speaker or commercial consultant for the company to disclose to the committee 
the existence and nature of his or her relationship with the company. 
 
9. Scholarships and Educational Funds 
a. Financial assistance for scholarships or other educational funds to permit medical 
students, residents, fellows, and other healthcare professionals in training to 
attend educational conferences may only be offered by the academic or training 
institution. 
 
10. Prohibition of Non-Educational and Practice-Related Items 
a. Providing items for healthcare professionals’ use that do not advance disease or 
treatment education are prohibited.  Examples include but are not limited to: 






b. Items intended for personal benefit of healthcare professionals (such as floral 
arrangements, artwork, music CDs or tickets to a sporting event) are prohibited. 
c. Payments in cash or cash equivalents (such as gift certificates) are prohibited. 
 
11. Educational Items 
a. Items designed primarily for education of patients or healthcare professionals 
must be $100 or less in value. 
b. Items designed primarily for the education of patients or healthcare professionals 
should not be offered on more than an occasional basis.  
 
12. Independence and Decision Making 
a. No grants, scholarships, subsidies, support, consulting contracts, or educational 
or practice related items should be provided or offered to a healthcare 
professional in exchange for prescribing products or for a commitment to 

















1.  Office of Inspector General (OIG)   
2.  Federal Trade Commission (FTC) 
3.  Division of Drug Marketing and Communication (DDMAC) 
 
Industry Regulations 














Table of Regulations 




Description of Regulation 
1 The manufacturer, sales representatives, or other agents of 
the company, may not offer payment or anything of value 
for patient referrals or in return for purchasing 
(prescriptions) 
2 Manufacturer should identify any remunerative 
relationship between itself (and its representatives) and 
persons or entities in a position to generate federal health 
care business for the manufacturer directly or indirectly 
3 When providing information to decision-makers, 
prescribers, or patients, the information must be complete, 
accurate and not misleading 
4 Manufacturer is prohibited from coupling a service that 
has no independent value in tandem with another service 
or program that confers a benefit on a referring provider 
5 Sales and marketing functions are prohibited from 
providing grants, nor can it be involved in any aspect of 
grant making 
6 Manufacturer should have no control over the speaker or 
content of the educational presentation 
7 Manufacturer must document grant making and 
educational presentation procedures and regularly monitor 
8 Any payments to cover the costs of "converting" from a 
competitor's product is prohibited 
9 Selective offers of remuneration (i.e., offers made to some 
but not all purchasers) are prohibited 
10 Relationships with formulary committee members should 
not include any renumeration from a manufacturer or its 
agents, nor to influence formulary decisions which are 
exclusive or restricted status 
11 Relationships with physicians and other persons and 
entities in a position to make or influence referrals should 






12 If goods or services provided by the manufacturers 
eliminate an expense that the physician would have 
otherwise incurred (i.e., have independent value to the 
physician), or if items or services are sold to a physician at 
less than their fair market value, the arrangement is 
prohibited 
13 "Switching" arrangements involve pharmaceuticcal 
manufacturers offering physicians or others cash payments 
or other benefits each time a patient's prescription is 
changed to the manufacturer's product from a competing 
product, is prohibited 
14 Consulting and advisory payments whereby 
pharmaceutical manufacturers frequently engage 
physicians and other health care professionals to furnish 
personal services as consultants or advisers to the 
manufactures must be at fair market value to small 
numbers of physicians for bona fide consulting or 
advisory services 
15 Compensating physicians for services directly or 
indirectly related to sales and marketing activities such as 
speaking, certain research, or preceptor or “shadowing” 
services is prohibited 
16 Payments for detailing (i.e., compensating physicians for 
time spent listening to sales representatives market 
pharmaceutical products), is prohibited 
17 Payments for time spent accessing web sites to view or 
listen to marketing information or perform “research” is 
prohibited 
18 Entertainment, recreation, travel and meals in association 
with information or marketing/ sales presentations are 
prohibited 
19 Gifts, gratuities, and other business courtesies are 
prohibited 
20 Promotional materials provided to healthcare professionals 
by or on behalf of a company should make properly 
substantiated claims and reflect the balance between risks 
and benefits 
21 Promotional materials provided to healthcare professionals 
by or on behalf of a company should be consistent with all 
other Food and Drug Administration (FDA) requirements 
governing such communications 
22 Occasional meals may be offered as a business courtesy to 
healthcare professionals (including members of their staff) 
attending sales/ marketing presentations provided the meal 





23 Occasional meals may be offered as a business courtesy to 
healthcare professionals (including members of their staff) 
attending sales/ marketing presentations as long as the 
meeting is not part of an entertainment or recreational 
event 
24 Occasional meals may be offered as a business courtesy to 
healthcare professionals (including members of their staff) 
attending sales/ marketing presentations so long as the 
presentations provide scientific or educational value. 
25 Meals offered in connection with informational 
presentations made by field sales representatives or their 
immediate managers should also be limited to in-office or 
in-hospital settings 
26 Inclusion of a healthcare professional's spouse or other 
guest in a meal accompanying an informational 
presentation made by or on behalf of a company is 
prohibited 
27 Offering "take-out" meals or meals to be eaten without a 
company representative being present is prohibited 
28 Companies are prohibited from providing any 
entertainment or recreational items including tickets to 
theatre or sporting events, sporting equipment, or leisure 
and vacation trips 
29 Giving of any subsidy directly to a healthcare professional 
by a company is prohibited 
30 Any financial support should be given to the CME 
provider, which, in turn, can use the money to reduce the 
overall CME registration fee for all participants 
31 The company is prohibited to provide any advice or 
guidance to the CME provider, even if asked by the 
provider, regarding the content or faculty for a particularly 
CME program funded by the company 
32 Financial support is prohibited for the costs of travel, 
lodging, or other personal expenses of non-faculty 
healthcare professionals attending CME 
33 Funding should not be offered to compensate for the time 
spent by healthcare professionals participating in the CME 
event 
34 A company should not provide meals directly at CME 
events, except that a CME provider at its own discretion 
may apply the financial support provided by a company 
for CME event to provide meals for all participants 
35 Any subsidy or financial support for professional meetings 





36 Financial support for professional meetings should be 
given directly to the conference’s sponsor, which, in turn, 
can use the money to reduce the overall conference 
registration fee for all attendees 
37 When companies underwrite medical conferences or 
meetings other than their own, responsibility for and 
control over the selection of content, faculty, educational 
methods, materials, and venue belongs to the organizers of 
the conference and may not be influence by the sponsoring 
company 
38 Financial support for the costs of travel, lodging, or other 
personal expenses are prohibited 
39 Consulting agreements are prohibited to serve as either 
inducements or rewards for prescribing or recommending 
a particular medicine or course of treatment 
40 A written contract must specify the nature of the 
consulting services to be provided and the basis for 
payment of those services 
41 A legitimate need for the consulting services must be 
clearly identified in advance of requesting the services and 
entering into arrangements with the prospective 
consultants 
42 The criteria for selecting consultants must be directly 
related to the identified purpose and the persons 
responsible for selecting the consultants have the expertise 
necessary to evaluate whether the particular healthcare 
professionals meet those criteria 
43 It is required that the number of healthcare professionals 
retained is not greater than the number reasonably 
necessary to achieve the identified purpose 
44 The retaining company must maintain records concerning 
and makes appropriate use of the services provided by 
consultants 
45 The venue and circumstances of any meeting with 
consultants are conducive to the consulting services and 
activities related to the services are the primary focus of 
the meeting; specifically, resorts are not appropriate 
venues 
46 Companies are prohibited to provide recreational or 
entertainment events in conjunction with consultant/ 
educational meetings 
47 It is prohibited to pay honoraria or travel or lodging 
expenses to non-faculty and non-consultant healthcare 
professional attendees at company-sponsored meetings, 





48 Company decisions regarding the selection or retention of 
healthcare professionals as speakers should be made based 
on defined criteria such as general medical expertise and 
reputation 
49 Each company should cap the total amount of annual 
compensation it will pay to an individual healthcare 
professional in connection with all speaking arrangements 
50 Each company should develop policies addressing the 
appropriate use of speakers, including utilization of 
speakers after training and the appropriate number of 
engagements for any particular speaker over time 
51 Speakers and their materials must clearly identify the 
company that is sponsoring the presentation 
52 Companies must monitor speaker programs for 
compliance with FDA regulatory requirements for 
communications on behalf of the company about its 
medicines 
53 Companies must require any healthcare professional who 
is a member of a committee that sets formularies or 
develops clinical guidelines and also serves as a speaker or 
commercial consultant for the company to disclose to the 
committee the existence and nature of his or her 
relationship with the company 
54 Financial assistance for scholarships or other educational 
funds to permit medical students, residents, fellows, and 
other healthcare professionals in training to attend 
educational conferences may only be offered by the 
academic or training institution 
55 Providing items for healthcare professionals’ use that do 
not advance disease or treatment education is prohibited.  
Examples include but are not limited to: pens, note pads, 
mugs and similar “reminder” items with company or 
product logos 
56 Items intended for personal benefit of healthcare 
professionals (such as floral arrangements, artwork, music 
CDs or tickets to a sporting event) are prohibited 
57 Payments in cash or cash equivalents (such as gift 
certificates) are prohibited 
58 Items designed primarily for education of patients or 
healthcare professionals must be $100 or less in value 
59 Items designed primarily for the education of patients or 
healthcare professionals should not be offered on more 





60 No grants, scholarships, subsidies, support, consulting 
contracts, or educational or practice related items should 
be provided or offered to a healthcare professional in 
exchange for prescribing products or for a commitment to 

















































Relationship Building (Reid, Plank, and Minton 1997) 
x1:  Ability to ask probing questions 
x2:  Listened to customer 
x3:  Ability to make a charismatic presentation  
x4:  Ability to work well with other people who are involved in the purchase 
 
(Adapted from industry interviews and focus groups) 
x16:  Follow up with customer 
 
Getting to Buy (Reid, Plank, and Minton 1997) 
x5:  Gain participation and got customer involved in the sales presentation 
x6:  Ability to use analogies and similes in his/her presentation to help customer see how it relates to          
his/her situation 
x7:  Ability to link his/her product/service attributes to customer needs 
x8: Could differentiate his/her product/service from the competition 
x9:  Ability to do “homework” on customer 
x10: Ability to handle objections raised by customer 
 
Planning 
(Moncrief, Marshall, and Lassk 2006) 
x11: Search out new leads 
x12: Pre-call planning/ targeting 
x17: Administrative activities/ documentation 
 
(Adapted from industry interviews and focus groups) 
x13: Conduct targeting activities 
x14: Designing sales plan 







Survey Cover Letter 
 
 
Research Study Title:  The Effect of Regulation on Selling Activities 
 





I am inviting you participate in a research project to study the effect of regulation on 
selling activities.  Along with this letter is a short questionnaire that asks a variety of 
questions about how you perceive specific regulations affect your selling activities.  The 
questionnaire contains only twenty (20) items and will take about 15 minutes to 
complete.  I guarantee that your responses will not be identified with you personally, are 
blinded, and completely anonymous.   
 
The results of this project will be used to complete my doctoral dissertation.  Through 
your participation I hope to develop a taxonomy (classification scheme) of regulations 
that accurately reflects their effect on selling activities by pharmaceutical sales people.  I 
hope to share my results by publishing them in a scientific journal as well as various 
public press outlets.   
 
This project has been approved by the Institutional Review Board (IRB) at Kennesaw 




John F. Riggs 
Doctor of Business Administration, Doctoral Candidate, A.B.D. 
Kennesaw State University 













































































































































































































































































































































































































































Customer Relationships through Communication 
x1:  Ability to ask probing questions 
x2:  Listened to customer 
x3:  Ability to make a charismatic presentation  
x4:  Ability to work well with other people who are involved in the  
purchase 
x16: Follow up with customer 
 
Factor 2 
Core Selling Skills 
x5:  Gain participation and got customer involved in the sales 
presentation 
x6:  Ability to use analogies and similes in his/her presentation to help 
customer see how it relates to his/her situation 
x7:  Ability to link his/her product/service attributes to customer needs 
x8:  Could differentiate his/her product/service from the competition 
x9:  Ability to do “homework” on customer 




x11: Search out new leads 
x12: Pre-call planning/ targeting 
x13: Conduct targeting activities 
x14: Designing sales plan 
 
 
 
 
